1
|
Marx C, Rabilloud M, Borson Chazot F, Tilikete C, Jouanneau E, Raverot G. A key role for conservative treatment in the management of pituitary apoplexy. Endocrine 2021; 71:168-177. [PMID: 32959228 DOI: 10.1007/s12020-020-02499-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Accepted: 09/11/2020] [Indexed: 10/23/2022]
Abstract
PURPOSE The management of pituitary apoplexy, a rare emergency neuroendocrine condition, is controversial. The aim of the present study is to compare the outcomes of patients with pituitary apoplexy managed either by a conservative or surgical approach. METHODS A retrospective cohort study including patients diagnosed between 2007 and 2018 in a tertiary French university hospital. Pituitary Apoplexy Score (PAS) was retrospectively applied in the perspective of therapeutic decision support. RESULTS Forty-six patients were treated for pituitary apoplexy either with conservative management (n = 27) or surgery (n = 19). At initial evaluation, visual field defects (VFD) and visual acuity impairment were more frequent in patients from the surgery group. At 1 year there were no statistical differences in the rates of complete/near-complete resolution of VFD (100 vs. 91.7%), visual acuity impairment (100 vs. 87.5%), and cranial nerve palsies (83.3 vs. 100%), between conservative and surgical treatment groups. There were more endocrine deficits at 1 year in the surgical group (p = 0.029). PAS (n = 41) was 3.4 on average in the early surgery group and 1.3 in the conservative treatment/delayed surgery group. Among patients with a score < 4, 31.3% were operated at first line and did not present better outcomes than patients managed conservatively. In all, 88.9% of patients with a score ≥ 4 underwent surgery. CONCLUSIONS PAS may be a reliable parameter for defining therapeutic strategy. Patients with non-severe and nonprogressive neuro-ophthalmological deficits can be managed conservatively without negative impact on outcomes, thus surgery should be reserved only for those patients with a PAS ≥ 4.
Collapse
Affiliation(s)
- Claire Marx
- Hospices Civils de Lyon, Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, 59 Pinel Boulevard, 69677, Bron, France.
- Lyon I University, F-69373, Lyon, France.
| | - Muriel Rabilloud
- Lyon I University, F-69373, Lyon, France
- I.f.c.s Hospices Civils de Lyon, 162 avenue Lacassagne, 75003, Lyon, France
| | - Françoise Borson Chazot
- Hospices Civils de Lyon, Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, 59 Pinel Boulevard, 69677, Bron, France
- Lyon I University, F-69373, Lyon, France
| | - Caroline Tilikete
- Lyon I University, F-69373, Lyon, France
- "Groupement Hospitalier Est" Hospices Civils de Lyon, Neuro-ophthalmology and Neuro-cognitive Unit, 69677, Bron, France
- CRNL INSERM U1028 CNRS UMR5292, ImpAct Team, F-69676, Bron, France
| | - Emmanuel Jouanneau
- Lyon I University, F-69373, Lyon, France
- Neurosurgery Department, "Groupement Hospitalier Est" Hospices Civils de Lyon, 69677, Bron, France
- INSERM U1052, CNRS, UMR5286, Cancer Research Center of Lyon, 69372, Lyon, France
| | - Gerald Raverot
- Hospices Civils de Lyon, Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, 59 Pinel Boulevard, 69677, Bron, France
- Lyon I University, F-69373, Lyon, France
- INSERM U1052, CNRS, UMR5286, Cancer Research Center of Lyon, 69372, Lyon, France
| |
Collapse
|
2
|
Vogrig A, Muñiz-Castrillo S, Joubert B, Picard G, Rogemond V, Skowron F, Egri M, Desestret V, Tilikete C, Psimaras D, Ducray F, Honnorat J. Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. Neurology 2020; 96:e866-e875. [PMID: 33318162 DOI: 10.1212/wnl.0000000000011340] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 10/12/2020] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To describe the spectrum, treatment, and outcome of cranial nerve disorders associated with immune checkpoint inhibitor (Cn-ICI). METHODS This nationwide retrospective cohort study on Cn-ICI (2015-2019) was conducted using the database of the French Refence Center. In addition, a systematic review of the literature (MEDLINE, Scopus, and Web of Science) for records published between 2010 and 2019 was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using the search terms cranial nerve or neuropathy or palsy and immune checkpoint inhibitors. RESULTS Among 67 cases with ICI-related neurologic toxicities diagnosed in our reference center, 9 patients with Cn-ICI were identified (7 men, 78%, median age 62 years [range 26-82 years]). Patients were receiving a combination of anti-cytotoxic T-lymphocyte antigen 4 and anti-programmed cell death 1 (PD-1)/PD-1 ligand (n = 5, 56%) or anti-PD-1 antibodies alone (n = 4, 44%). Cn-ICI involved optic (n = 3), vestibulocochlear (n = 3), abducens (n = 2), facial (n = 2), and oculomotor (n = 1) nerves. Two patients had involvement of 2 different cranial nerves. Treatment comprised corticosteroids (n = 8, 89%), ICI permanent discontinuation (n = 7, 78%), plasma exchange (n = 2, 22%), and IV immunoglobulin (n = 1, 11%). Median follow-up was 11 months (range 1-41 months). In 3 cases (33%), neurologic deficit persisted/worsened despite treatment: 2 optic and 1 vestibulocochlear. Among cases from the literature and the present series combined (n = 39), the most commonly affected cranial nerves were facial (n = 13, 33%), vestibulocochlear (n = 8, 21%), optic (n = 7, 18%), and abducens (n = 4, 10%). Trigeminal, oculomotor, and glossopharyngeal nerves were less frequently affected (total n = 7). CONCLUSION Cranial nerve disorders can complicate treatment with ICIs. Approximately one-third of the patients had persisting deficits, most frequently involving hearing and vision loss.
Collapse
Affiliation(s)
- Alberto Vogrig
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - Sergio Muñiz-Castrillo
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - Bastien Joubert
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - Géraldine Picard
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - Véronique Rogemond
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - François Skowron
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - Madalina Egri
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - Virginie Desestret
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - Caroline Tilikete
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - Dimitri Psimaras
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - François Ducray
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France
| | - Jérôme Honnorat
- From the French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (A.V., S.M.-C., B.J., G.P., V.R., V.D., D.P., F.D., J.H.) and Neuro-Cognition and Neuro-Ophthalmology Department (V.D., C.T.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team, NeuroMyoGene Institute (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H.), INSERM U1217/CNRS UMR5310; University Claude Bernard Lyon 1 (A.V., S.M.-C., B.J., G.P., V.R., V.D., F.D., J.H., C.T.), Université de Lyon, Lyon, France; Dermatology Department (F.S.), Centre Hospitalier de Valence; Neurology Department (M.E.), Centre Hospitalier de Libourne; Team ImpAct (C.T.), Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292; and Neurology Department 2-Mazarin (D.P.), Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere Groupe, Hospitalier Pitie-Salpetriere et Universite Pierre et Marie Curie-Paris 6, AP-HP, France.
| |
Collapse
|
3
|
Louapre C, Maillart E, Papeix C, Zeidan S, Biotti D, Lepine Z, Wahab A, Zedet M, Labauge P, Tilikete C, Pique J, Tourbah A, Mathey G, Dimitri Boulos D, Branger P, Kremer LD, Marignier R, Collongues N, De Seze J. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. Eur J Neurol 2020; 28:3461-3466. [PMID: 33103295 DOI: 10.1111/ene.14612] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 09/05/2020] [Accepted: 10/18/2020] [Indexed: 12/15/2022]
Abstract
BACKGROUND Outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown. METHODS We conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID-19 between 1 March 2020 and 30 June 2020. Main outcome was COVID-19 severity score assessed on a seven-point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death). RESULTS Fifteen cases (mean [SD] age: 39.3 [14.3] years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24-year-old patient with positive aquaporine-4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti-CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean [SD] age: 37.0 [13.4] years), with a longer disease duration (mean [SD]: 8.3 [6.3] years) and had a lower expanded disability severity score (EDSS) score (median [range] EDSS: 2.5 [0-4]) relative to patients requiring hospitalization (mean [SD] age: 44.0 [16.4] years, mean [SD] disease duration: 5.8 [5.5] years, median [range] EDSS: 4 [0-6.5]). CONCLUSIONS COVID-19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID-19; however, we recommend personal protective measures to reduce risk of SARS-CoV-2 infection in this immunocompromised population.
Collapse
Affiliation(s)
- Céline Louapre
- Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Institut du Cerveau, CIC Neuroscience, ICM, Hôpital de la Pitié Salpêtrière, Sorbonne Université, Paris, France
| | - Elisabeth Maillart
- Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Institut du Cerveau, CIC Neuroscience, ICM, Hôpital de la Pitié Salpêtrière, Sorbonne Université, Paris, France
| | - Caroline Papeix
- Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Institut du Cerveau, CIC Neuroscience, ICM, Hôpital de la Pitié Salpêtrière, Sorbonne Université, Paris, France
| | - Sinead Zeidan
- Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Institut du Cerveau, CIC Neuroscience, ICM, Hôpital de la Pitié Salpêtrière, Sorbonne Université, Paris, France
| | - Damien Biotti
- Pole des Neurosciences, B4 Neurology Unit, Centre de ressources et de compétences Sclérose en plaques, CHU Purpan, Toulouse, France
| | - Zoé Lepine
- Pole des Neurosciences, B4 Neurology Unit, Centre de ressources et de compétences Sclérose en plaques, CHU Purpan, Toulouse, France
| | - Abir Wahab
- Service de Neurologie et CRC SEP, Groupe Hospitalier Henri Mondor, APHP, UPEC Université, Créteil, France
| | - Mickael Zedet
- Unité de neurologie inflammatoire, Département de Neurologie, Hôpital Roger Salengro, Chu de Lille, Lille, France
| | - Pierre Labauge
- Département de neurologie, CHU de Montpellier, Montpellier, France
| | - Caroline Tilikete
- Equipe impact, Service de Neurocognition et Neuro-ophtalmologie, Groupe Hospitalier Est, Centre de Recherche en Neurosciences de Lyon, Hospices Civils de Lyon, Université de Lyon, Lyon, France
| | - Julie Pique
- Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), Service de neurologie, sclérose en plaques, Pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Lyon, France
| | - Ayman Tourbah
- Service de Neurologie, Hôpital Raymond Poincaré, UFR Simone Veil UVSQ, Université Paris Saclay, Garches, France
| | - Guillaume Mathey
- Service de neurologie, Centre Régional Hospitalo-Universitaire de Nancy, Hôpital Central, Nancy, France.,Université de Lorraine, Vandoeuvre-lès-Nancy, France
| | | | - Pierre Branger
- Service de Neurologie, CHU de Caen Normandie, Caen, France
| | | | - Romain Marignier
- Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), Service de neurologie, sclérose en plaques, Pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Lyon, France
| | - Nicolas Collongues
- Service de Neurologie and CIC INSERM 1434, CHU de Strasbourg, Strasbourg, France
| | - Jérôme De Seze
- Service de Neurologie and CIC INSERM 1434, CHU de Strasbourg, Strasbourg, France
| |
Collapse
|
4
|
Blini E, Tilikete C, Chelazzi L, Farnè A, Hadj-Bouziane F. The role of the vestibular system in value attribution to positive and negative reinforcers. Cortex 2020; 133:215-235. [PMID: 33130427 DOI: 10.1016/j.cortex.2020.09.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 09/03/2020] [Accepted: 09/03/2020] [Indexed: 01/06/2023]
Abstract
Somatic inputs originating from bioregulatory processes can guide cognition and behavior. One such bodily signal, mostly overlooked so far, is represented by visuo-vestibular coupling and its alteration, which in extreme cases may result in motion sickness. We argued that the inherently perturbed interoceptive state that follows can be a powerful determinant of human motivated behavior, resulting in a blunted response to appetitive stimuli and an exaggerated response to noxious ones. We sought to assess such differential impact of visuo-vestibular mismatches on value through a task involving conflict monitoring. We therefore administered to 42 healthy participants a modified version of the Flankers task, in which distractors (arrows, pointing in either a congruent or incongruent direction) signaled the availability of monetary incentives (gains, losses, or neutral trials). While performing the task, participants received either galvanic vestibular stimulation (GVS), or sham stimulation. We have found impaired behavioral performances when value, which was attached to task-irrelevant information, was at stake. Gains and losses, interestingly, dissociated, and only the latter caused enhanced interference costs in the task, suggesting that negative incentives may be more effective in capturing human attention than positive ones. Finally, we have found some weak evidence for GVS to further increase the processing of losses, as suggested by even larger interference costs in this condition. Results were, however, overall ambiguous, and suggest that much more research is needed to better understand the link between the vestibular system and motivation.
Collapse
Affiliation(s)
- Elvio Blini
- Integrative Multisensory Perception Action & Cognition Team (ImpAct), INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center (CRNL), Lyon, France; University of Lyon, Lyon, France; Department of General Psychology, University of Padova, Padova, Italy.
| | - Caroline Tilikete
- Integrative Multisensory Perception Action & Cognition Team (ImpAct), INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center (CRNL), Lyon, France; University of Lyon, Lyon, France; Hospices Civils de Lyon, Neuro-Ophthalmology and Neurocognition, Hôpital Neurologique Pierre Wertheimer, Bron, France
| | - Leonardo Chelazzi
- Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; National Institute of Neuroscience - Verona Unit, Verona, Italy
| | - Alessandro Farnè
- Integrative Multisensory Perception Action & Cognition Team (ImpAct), INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center (CRNL), Lyon, France; University of Lyon, Lyon, France; Hospices Civils de Lyon, Neuro-Immersion Platform, Lyon, France
| | - Fadila Hadj-Bouziane
- Integrative Multisensory Perception Action & Cognition Team (ImpAct), INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center (CRNL), Lyon, France; University of Lyon, Lyon, France.
| |
Collapse
|
5
|
Specovius S, Zimmermann HG, Oertel FC, Chien C, Bereuter C, Cook LJ, Lana Peixoto MA, Fontenelle MA, Kim HJ, Hyun JW, Jung SK, Palace J, Roca-Fernandez A, Diaz AR, Leite MI, Sharma SM, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, Dcunha A, Aktas O, Ringelstein M, Albrecht P, May E, Tongco C, Leocani L, Pisa M, Radaelli M, Martinez-Lapiscina EH, Stiebel-Kalish H, Hellmann M, Lotan I, Siritho S, de Seze J, Senger T, Havla J, Marignier R, Tilikete C, Cobo Calvo A, Bichuetti DB, Tavares IM, Asgari N, Soelberg K, Altintas A, Yildirim R, Tanriverdi U, Jacob A, Huda S, Rimler Z, Reid A, Mao-Draayer Y, de Castillo IS, Yeaman MR, Smith TJ, Brandt AU, Paul F. Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). BMJ Open 2020; 10:e035397. [PMID: 33122310 PMCID: PMC7597491 DOI: 10.1136/bmjopen-2019-035397] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
PURPOSE Optical coherence tomography (OCT) captures retinal damage in neuromyelitis optica spectrum disorders (NMOSD). Previous studies investigating OCT in NMOSD have been limited by the rareness and heterogeneity of the disease. The goal of this study was to establish an image repository platform, which will facilitate neuroimaging studies in NMOSD. Here we summarise the profile of the Collaborative OCT in NMOSD repository as the initial effort in establishing this platform. This repository should prove invaluable for studies using OCT to investigate NMOSD. PARTICIPANTS The current cohort includes data from 539 patients with NMOSD and 114 healthy controls. These were collected at 22 participating centres from North and South America, Asia and Europe. The dataset consists of demographic details, diagnosis, antibody status, clinical disability, visual function, history of optic neuritis and other NMOSD defining attacks, and OCT source data from three different OCT devices. FINDINGS TO DATE The cohort informs similar demographic and clinical characteristics as those of previously published NMOSD cohorts. The image repository platform and centre network continue to be available for future prospective neuroimaging studies in NMOSD. For the conduct of the study, we have refined OCT image quality criteria and developed a cross-device intraretinal segmentation pipeline. FUTURE PLANS We are pursuing several scientific projects based on the repository, such as analysing retinal layer thickness measurements, in this cohort in an attempt to identify differences between distinct disease phenotypes, demographics and ethnicities. The dataset will be available for further projects to interested, qualified parties, such as those using specialised image analysis or artificial intelligence applications.
Collapse
Affiliation(s)
- Svenja Specovius
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Hanna G Zimmermann
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Frederike Cosima Oertel
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Claudia Chien
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Charlotte Bereuter
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Lawrence J Cook
- Department of Pediatrics, University of Utah, Salt Lake CIty, Utah, USA
| | | | | | - Ho Jin Kim
- Department of Neurology, National Cancer Center, Goyang, Republic of Korea
| | - Jae-Won Hyun
- Department of Neurology, National Cancer Center, Goyang, Republic of Korea
| | - Su-Kyung Jung
- Department of Ophthalmology, National Cancer Center, Goyang, Republic of Korea
| | - Jacqueline Palace
- Department of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK
| | | | - Alejandro Rubio Diaz
- Department of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK
| | - Maria Isabel Leite
- Department of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK
| | - Srilakshmi M Sharma
- Department of Ophthalmology, Oxford University Hospitals, National Health Service Trust, Oxford, UK
| | - Fereshte Ashtari
- Kashani MS Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Rahele Kafieh
- School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Alireza Dehghani
- Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohsen Pourazizi
- Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Lekha Pandit
- Department of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, India
| | - Anitha Dcunha
- Department of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, India
| | - Orhan Aktas
- Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Marius Ringelstein
- Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- Department of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Philipp Albrecht
- Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Eugene May
- Swedish Neuroscience Institute Neuro-Ophthalmology, Seattle, Washington, USA
| | - Caryl Tongco
- Swedish Neuroscience Institute Neuro-Ophthalmology, Seattle, Washington, USA
| | - Letizia Leocani
- Neurological Department and Institute of Experimental Neurology (INSPE) Scientific Institute, Hospital San Raffaele; and University Vita-Salute San Raffaele, Milan, Italy
| | - Marco Pisa
- Neurological Department and Institute of Experimental Neurology (INSPE) Scientific Institute, Hospital San Raffaele; and University Vita-Salute San Raffaele, Milan, Italy
| | - Marta Radaelli
- Neurological Department and Institute of Experimental Neurology (INSPE) Scientific Institute, Hospital San Raffaele; and University Vita-Salute San Raffaele, Milan, Italy
| | - Elena H Martinez-Lapiscina
- Hospital Clinic of Barcelona-Institut d'Investigacions, Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain
| | - Hadas Stiebel-Kalish
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- Neuro-Ophthalmology Division, Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel
| | - Mark Hellmann
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Itay Lotan
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Sasitorn Siritho
- Division of Neurology, Department of Medicine, Siriraj Hospital and Bumrungrad International Hospital, Bangkok, Thailand
| | - Jérôme de Seze
- Neurology Service, University Hospital of Strasbourg, Strasbourg, France
| | - Thomas Senger
- Neurology Service, University Hospital of Strasbourg, Strasbourg, France
| | - Joachim Havla
- Institute of Clinical Neuroimmunology, University Hospital, Ludwig Maximilians University, Munich, Germany
| | - Romain Marignier
- Neurology, Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France
| | - Caroline Tilikete
- Department of Neuro-Ophthalmology, Hospices Civils de Lyon, Lyon, France
| | - Alvaro Cobo Calvo
- Neurology, Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France
| | - Denis Bernardi Bichuetti
- Departamento de Neurologia e Neurocirurgia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
| | - Ivan Maynart Tavares
- Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
| | - Nasrin Asgari
- Departments of Neurology, Slagelse Hospital, Slagelse, Denmark
- Institutes of Regional Health Research and Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | - Kerstin Soelberg
- Departments of Neurology, Slagelse Hospital, Slagelse, Denmark
- Institutes of Regional Health Research and Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | - Ayse Altintas
- Neurology Department, School of Medicine, Koc University and Istanbul University - Cerrahpasa School of Medicine, Istanbul, Turkey
| | - Rengin Yildirim
- Department of Ophthalmology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
| | - Uygur Tanriverdi
- Neurology Department Istanbul, Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey
| | - Anu Jacob
- Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Saif Huda
- Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Zoe Rimler
- Department of Neurology, NYU Multiple Sclerosis Comprehensive Care Center, NYU School of Medicine, New York, New York, USA
| | - Allyson Reid
- Department of Neurology, NYU Multiple Sclerosis Comprehensive Care Center, NYU School of Medicine, New York, New York, USA
| | - Yang Mao-Draayer
- Department of Neurology, University of Michigan Medical School, Ann Arbor, Michigan, USA
| | | | - Michael R Yeaman
- Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
| | - Terry J Smith
- Departments of Ophthalmology and Visual Sciences, Kellogg Eye Center, Ann Arbor, Michigan, USA
- Division of Metabolism, Endocrine and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
| | - Alexander U Brandt
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Department of Neurology, University of California, Irvine, California, USA
| | - Friedemann Paul
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Department of Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| |
Collapse
|
6
|
Abstract
Sarcoidosis is one of the leading causes of inflammatory eye disease. Any part of the eye and its adnexal tissues can be involved. Uveitis and optic neuropathy are the main manifestations, which may require systemic treatment. Two groups of patients with sarcoid uveitis can be distinguished: one of either sex and any ethnicity in which ophthalmological findings are various and another group of elderly Caucasian women with mostly chronic posterior uveitis. Clinically isolated uveitis revealing sarcoidosis remains a strictly ocular condition in a large majority of cases. Although it can be a serious condition involving functional prognosis, early recognition in addition to a growing therapeutic arsenal (including intravitreal implant) has improved the visual prognosis of the disease in recent years. Systemic corticosteroids are indicated when uveitis does not respond to topical corticosteroids or when there is bilateral posterior involvement, especially macular edema. In up to 30% of the cases that require an unacceptable dosage of corticosteroids to maintain remission, additional immunosuppression is used, especially methotrexate. As with other forms of severe noninfectious uveitis, monoclonal antibodies against tumor necrosis factor-α have been used. However, only very rarely does sarcoid uveitis fail to respond to combined corticosteroids and methotrexate therapy, a situation that should suggest either poor adherence or another granulomatous disease. Optic neuropathy often affects women of African and Caribbean origins. Some authors recommend that patients should be treated with high-dose of corticosteroids and concurrent immunosuppression from the onset of this manifestation, which is associated with a poorer outcome.
Collapse
Affiliation(s)
- Pascal Sève
- Department of Internal Medicine, Hopital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France.,Hospices Civils de Lyon, Pôle IMER, Lyon, France.,University Claude Bernard-Lyon 1, HESPER EA 7425, Univ. Lyon, Lyon, France
| | - Yvan Jamilloux
- Department of Internal Medicine, Hopital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France
| | - Caroline Tilikete
- Department of Internal Medicine, Hopital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France
| | - Mathieu Gerfaud-Valentin
- Department of Internal Medicine, Hopital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France
| | - Laurent Kodjikian
- Neurology D and Neuro-Ophthalmology Unit, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France.,Université de Lyon, Lyon 1 University, Lyon, France.,Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR5292, Team ImpAct, Bron, France.,Department of Ophthalmology, Hopital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France
| | - Thomas El Jammal
- Department of Internal Medicine, Hopital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France
| |
Collapse
|
7
|
Tilikete C. Ocular motility disorders with special emphasis on multiple sclerosis. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
8
|
Laurens B, Planche V, Cubizolle S, Declerck L, Dupouy S, Formaglio M, Koric L, Seassau M, Tilikete C, Vighetto A, Ceccaldi M, Tison F. A Spatial Decision Eye-Tracking Task in Patients with Prodromal and Mild Alzheimer’s Disease. J Alzheimers Dis 2019; 71:613-621. [DOI: 10.3233/jad-190549] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- Brice Laurens
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
- CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France
| | - Vincent Planche
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
- CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France
| | - Stéphanie Cubizolle
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
| | - Léa Declerck
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
| | - Sandrine Dupouy
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
- CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France
| | - Maïté Formaglio
- Département de Neurologie cognitive et de Neuro-ophtalmologie, Université Lyon 1 et Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France
| | - Lejla Koric
- Département de Neurologie et de Neuropsychologie, Aix Marseille Université, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | | | - Caroline Tilikete
- Département de Neurologie cognitive et de Neuro-ophtalmologie, Université Lyon 1 et Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France
| | - Alain Vighetto
- Département de Neurologie cognitive et de Neuro-ophtalmologie, Université Lyon 1 et Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France
| | - Mathieu Ceccaldi
- Département de Neurologie et de Neuropsychologie, Aix Marseille Université, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - Françcois Tison
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
- CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France
| |
Collapse
|
9
|
Renaud M, Moreira MC, Ben Monga B, Rodriguez D, Debs R, Charles P, Chaouch M, Ferrat F, Laurencin C, Vercueil L, Mallaret M, M'Zahem A, Pacha LA, Tazir M, Tilikete C, Ollagnon E, Ochsner F, Kuntzer T, Jung HH, Beis JM, Netter JC, Djamshidian A, Bower M, Bottani A, Walsh R, Murphy S, Reiley T, Bieth É, Roelens F, Poll-The BT, Lourenço CM, Jardim LB, Straussberg R, Landrieu P, Roze E, Thobois S, Pouget J, Guissart C, Goizet C, Dürr A, Tranchant C, Koenig M, Anheim M. Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1. JAMA Neurol 2019; 75:495-502. [PMID: 29356829 DOI: 10.1001/jamaneurol.2017.4373] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Importance Ataxia with oculomotor apraxia type 1 (AOA1) is an autosomal recessive cerebellar ataxia due to mutations in the aprataxin gene (APTX) that is characterized by early-onset cerebellar ataxia, oculomotor apraxia, axonal motor neuropathy, and eventual decrease of albumin serum levels. Objectives To improve the clinical, biomarker, and molecular delineation of AOA1 and provide genotype-phenotype correlations. Design, Setting, and Participants This retrospective analysis included the clinical, biological (especially regarding biomarkers of the disease), electrophysiologic, imaging, and molecular data of all patients consecutively diagnosed with AOA1 in a single genetics laboratory from January 1, 2002, through December 31, 2014. Data were analyzed from January 1, 2015, through January 31, 2016. Main Outcomes and Measures The clinical, biological, and molecular spectrum of AOA1 and genotype-phenotype correlations. Results The diagnosis of AOA1 was confirmed in 80 patients (46 men [58%] and 34 women [42%]; mean [SD] age at onset, 7.7 [7.4] years) from 51 families, including 57 new (with 8 new mutations) and 23 previously described patients. Elevated levels of α-fetoprotein (AFP) were found in 33 patients (41%); hypoalbuminemia, in 50 (63%). Median AFP level was higher in patients with AOA1 (6.0 ng/mL; range, 1.1-17.0 ng/mL) than in patients without ataxia (3.4 ng/mL; range, 0.8-17.2 ng/mL; P < .01). Decreased albumin levels (ρ = -0.532) and elevated AFP levels (ρ = 0.637) were correlated with disease duration. The p.Trp279* mutation, initially reported as restricted to the Portuguese founder haplotype, was discovered in 53 patients with AOA1 (66%) with broad white racial origins. Oculomotor apraxia was found in 49 patients (61%); polyneuropathy, in 74 (93%); and cerebellar atrophy, in 78 (98%). Oculomotor apraxia correlated with the severity of ataxia and mutation type, being more frequent with deletion or truncating mutations (83%) than with presence of at least 1 missense variant (17%; P < .01). Mean (SD) age at onset was higher for patients with at least 1 missense mutation (17.7 [11.4] vs 5.2 [2.6] years; P < .001). Conclusions and Relevance The AFP level, slightly elevated in a substantial fraction of patients, may constitute a new biomarker for AOA1. Oculomotor apraxia may be an optional finding in AOA1 and correlates with more severe disease. The p.Trp279* mutation is the most frequent APTX mutation in the white population. APTX missense mutations may be associated with a milder phenotype.
Collapse
Affiliation(s)
- Mathilde Renaud
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire, Institut National de la Santé et de la Recherche Medicale (INSERM)-U964, Centre National de la Recherche Scientifique (CNRS)-Unité Mixte de Recherché (UMR) 7104, Université de Strasbourg, Illkirch, France.,Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Maria-Céu Moreira
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Institut National de la Santé et de la Recherche Medicale (INSERM)-U964, Centre National de la Recherche Scientifique (CNRS)-Unité Mixte de Recherché (UMR) 7104, Université de Strasbourg, Illkirch, France
| | - Bondo Ben Monga
- Faculté de Médecine et Ecole de Santé Publique, Université de Lubumbashi, Lubumbashi, République Démocratique du Congo
| | - Diana Rodriguez
- Service de Neuropédiatrie, Hôpital d'Enfants Armand-Trousseau, Paris, France.,Centre de Référence de Neurogénétique, Hôpital Armand-Trousseau, Hôpitaux Universitaires Est Parisien, Assistance Publique-Hôpitaux de Paris, Paris, France.,Groupe de Recherch Clinique ConCer-LD, Sorbonne Universités, l'Université Pierre-et-Marie-Curie, Université Paris 06, Paris, France.,Neuroprotection du Cerveau en Développement, INSERM U1141, Paris, France
| | - Rabab Debs
- Département de Génétique, Hôpital de La Pitié-Salpétrière, Paris, France
| | - Perrine Charles
- Département de Génétique, Hôpital de La Pitié-Salpétrière, Paris, France
| | - Malika Chaouch
- Service de Neurologie, Etablissement Hospitalier Spécialisé, Algers, Algeria
| | - Farida Ferrat
- Service de Neurologie, Etablissement Hospitalier Spécialisé de Ben Aknoun, Algers, Algeria
| | - Chloé Laurencin
- Service de Neurologie C, Hopital Neurologique, Hospices Civils de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.,CNRS, Institut des Sciences Cognitives, UMR 5229, Bron, France
| | - Laurent Vercueil
- Exploration Fonctionnelle du Système Nerveux, Pôle de Psychiatrie, Neurologie et Rééducation Neurologique, Centre Hospitalier Universitaire (CHU) Grenoble, Grenoble, France.,INSERM U836, Grenoble Institut des Neurosciences, Bâtiment Edmond J. Safra, Chemin Fortuné Ferrini, La Tronche, France
| | - Martial Mallaret
- Exploration Fonctionnelle du Système Nerveux, Pôle de Psychiatrie, Neurologie et Rééducation Neurologique, Centre Hospitalier Universitaire (CHU) Grenoble, Grenoble, France
| | | | | | - Meriem Tazir
- Service de Neurologie, CHU Mustapha, Algers, Algeria
| | - Caroline Tilikete
- Service de Neuro-ophtalmologie, Hôpital Neurologique, CHU Lyon, Bron, France
| | | | | | | | - Hans H Jung
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - Jean-Marie Beis
- Institut Régional de Médecine Physique et de Réadaptation, Centre de Lay-Saint-Christophe, France
| | | | - Atbin Djamshidian
- Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
| | - Mattew Bower
- Department of Neurology, University of Minnesota Health, Minneapolis, Minnesota
| | - Armand Bottani
- Service de Génétique, Hôpitaux Universitaires de Genève, Genève, Suisse
| | - Richard Walsh
- Academic Unit of Neurology, Trinity College Dublin, Dublin, Ireland.,National Ataxia Clinic, Adelaide and Meath Hospital Dublin, National Children's Hospital, Dublin, Ireland
| | - Sinead Murphy
- National Ataxia Clinic, Adelaide and Meath Hospital Dublin, National Children's Hospital, Dublin, Ireland
| | - Thomas Reiley
- Department of Public Health and Environment, Greeley, Colorado
| | - Éric Bieth
- Service de Génétique Médicale, Hopital Purpan, Toulouse, France
| | | | - Bwee Tien Poll-The
- Pediatric Neurology, Emma Children's Hospital, University of Amsterdam, Amsterdam, the Netherlands
| | - Charles Marques Lourenço
- Neurogenetics Unit, School of Medicine of Ribeirao Preto, University of São Paulo, São Paulo, Brazil
| | - Laura Bannach Jardim
- Medical Genetics Service, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Rachel Straussberg
- Neurogenetics Clinic, Department of Child Neurology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.,Sackler School of Medicine Tel Aviv University, Ramat Aviv, Israel
| | - Pierre Landrieu
- Service de Neurologie Pédiatrique, Hôpital Bicêtre, Paris, France
| | - Emmanuel Roze
- Département de Génétique, Hôpital de La Pitié-Salpétrière, Paris, France
| | - Stéphane Thobois
- Service de Neurologie C, Hopital Neurologique, Hospices Civils de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.,CNRS, Institut des Sciences Cognitives, UMR 5229, Bron, France
| | - Jean Pouget
- Service de Neurologie, Hôpital de la Timone, Marseille, France
| | - Claire Guissart
- Laboratoire de Génétique de Maladies Rares EA7402, Institut Universitaire de Recherche Clinique, Université de Montpellier, CHU Montpellier, Montpellier, France
| | - Cyril Goizet
- Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.,INSERM U1211, Laboratoire Maladies Rares Génétique et Métabolisme, Université de Bordeaux, Bordeaux, France
| | - Alexandra Dürr
- Département de Génétique, Hôpital de La Pitié-Salpétrière, Paris, France
| | - Christine Tranchant
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire, Institut National de la Santé et de la Recherche Medicale (INSERM)-U964, Centre National de la Recherche Scientifique (CNRS)-Unité Mixte de Recherché (UMR) 7104, Université de Strasbourg, Illkirch, France.,Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Michel Koenig
- Laboratoire de Génétique de Maladies Rares EA7402, Institut Universitaire de Recherche Clinique, Université de Montpellier, CHU Montpellier, Montpellier, France
| | - Mathieu Anheim
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire, Institut National de la Santé et de la Recherche Medicale (INSERM)-U964, Centre National de la Recherche Scientifique (CNRS)-Unité Mixte de Recherché (UMR) 7104, Université de Strasbourg, Illkirch, France.,Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France
| |
Collapse
|
10
|
Abstract
The vestibulo-ocular reflex maintains gaze stabilization during angular or linear head accelerations, allowing adequate dynamic visual acuity. In case of bilateral vestibular hypofunction, patients use saccades to compensate for the reduced vestibulo-ocular reflex function, with covert saccades occurring even during the head displacement. In this study, we questioned whether covert saccades help maintain dynamic visual acuity, and evaluated which characteristic of these saccades are the most relevant to improve visual function. We prospectively included 18 patients with chronic bilateral vestibular hypofunction. Subjects underwent evaluation of dynamic visual acuity in the horizontal plane as well as video recording of their head and eye positions during horizontal head impulse tests in both directions (36 ears tested). Frequency, latency, consistency of covert saccade initiation, and gain of covert saccades as well as residual vestibulo-ocular reflex gain were calculated. We found no correlation between residual vestibulo-ocular reflex gain and dynamic visual acuity. Dynamic visual acuity performance was however positively correlated with the frequency and gain of covert saccades and negatively correlated with covert saccade latency. There was no correlation between consistency of covert saccade initiation and dynamic visual acuity. Even though gaze stabilization in space during covert saccades might be of very short duration, these refixation saccades seem to improve vision in patients with bilateral vestibular hypofunction during angular head impulses. These findings emphasize the need for specific rehabilitation technics that favor the triggering of covert saccades. The physiological origin of covert saccades is discussed.
Collapse
Affiliation(s)
- R Hermann
- Hospices Civils de Lyon, ENT, Cervico-Facial Surgery and Audiophonology, Hôpital Edouard Herriot, Lyon, France
- INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, IMPACT Team, Lyon, France
- Lyon I University, Lyon, France
| | - D Pelisson
- INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, IMPACT Team, Lyon, France
- Lyon I University, Lyon, France
| | - O Dumas
- French Vestibular Rehabilitation Society, Lyon, France
| | - Ch Urquizar
- INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, IMPACT Team, Lyon, France
| | - E Truy
- Hospices Civils de Lyon, ENT, Cervico-Facial Surgery and Audiophonology, Hôpital Edouard Herriot, Lyon, France
- INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, IMPACT Team, Lyon, France
- Lyon I University, Lyon, France
| | - C Tilikete
- INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, IMPACT Team, Lyon, France.
- Lyon I University, Lyon, France.
- Hospices Civils de Lyon, Neuro-Ophthalmology Unit, Hopital Neurologique et Neurochirurgical P Wertheimer, Lyon, France.
| |
Collapse
|
11
|
Metzger A, Pisella L, Vighetto A, Joubert B, Honnorat J, Tilikete C, Desestret V. Balint syndrome in anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflamm 2019; 6:e532. [PMID: 30588484 PMCID: PMC6299677 DOI: 10.1212/nxi.0000000000000532] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Accepted: 11/08/2018] [Indexed: 11/17/2022]
Affiliation(s)
- Aude Metzger
- Service de neuro-ophtalmologie et neuro-cognition (A.M., A.V., C.T., V.D.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; IMPACT-Integrative, Multisensory (L.P., A.V., C.T.), Perception, Action and Cognition Team, Centre de recherche des Neurosciences de Lyon (CRNL); Université Claude Bernard Lyon 1 (A.V., B.J., J.H., C.T., V.D.); Centre de référence français des syndromes paranéoplasiques (B.J., J.H.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; and Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310 (B.J., J.H., V.D.), équipe synaptopathies et anticorps (SYNATAC), Lyon, France
| | - Laure Pisella
- Service de neuro-ophtalmologie et neuro-cognition (A.M., A.V., C.T., V.D.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; IMPACT-Integrative, Multisensory (L.P., A.V., C.T.), Perception, Action and Cognition Team, Centre de recherche des Neurosciences de Lyon (CRNL); Université Claude Bernard Lyon 1 (A.V., B.J., J.H., C.T., V.D.); Centre de référence français des syndromes paranéoplasiques (B.J., J.H.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; and Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310 (B.J., J.H., V.D.), équipe synaptopathies et anticorps (SYNATAC), Lyon, France
| | - Alain Vighetto
- Service de neuro-ophtalmologie et neuro-cognition (A.M., A.V., C.T., V.D.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; IMPACT-Integrative, Multisensory (L.P., A.V., C.T.), Perception, Action and Cognition Team, Centre de recherche des Neurosciences de Lyon (CRNL); Université Claude Bernard Lyon 1 (A.V., B.J., J.H., C.T., V.D.); Centre de référence français des syndromes paranéoplasiques (B.J., J.H.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; and Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310 (B.J., J.H., V.D.), équipe synaptopathies et anticorps (SYNATAC), Lyon, France
| | - Bastien Joubert
- Service de neuro-ophtalmologie et neuro-cognition (A.M., A.V., C.T., V.D.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; IMPACT-Integrative, Multisensory (L.P., A.V., C.T.), Perception, Action and Cognition Team, Centre de recherche des Neurosciences de Lyon (CRNL); Université Claude Bernard Lyon 1 (A.V., B.J., J.H., C.T., V.D.); Centre de référence français des syndromes paranéoplasiques (B.J., J.H.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; and Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310 (B.J., J.H., V.D.), équipe synaptopathies et anticorps (SYNATAC), Lyon, France
| | - Jérôme Honnorat
- Service de neuro-ophtalmologie et neuro-cognition (A.M., A.V., C.T., V.D.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; IMPACT-Integrative, Multisensory (L.P., A.V., C.T.), Perception, Action and Cognition Team, Centre de recherche des Neurosciences de Lyon (CRNL); Université Claude Bernard Lyon 1 (A.V., B.J., J.H., C.T., V.D.); Centre de référence français des syndromes paranéoplasiques (B.J., J.H.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; and Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310 (B.J., J.H., V.D.), équipe synaptopathies et anticorps (SYNATAC), Lyon, France
| | - Caroline Tilikete
- Service de neuro-ophtalmologie et neuro-cognition (A.M., A.V., C.T., V.D.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; IMPACT-Integrative, Multisensory (L.P., A.V., C.T.), Perception, Action and Cognition Team, Centre de recherche des Neurosciences de Lyon (CRNL); Université Claude Bernard Lyon 1 (A.V., B.J., J.H., C.T., V.D.); Centre de référence français des syndromes paranéoplasiques (B.J., J.H.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; and Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310 (B.J., J.H., V.D.), équipe synaptopathies et anticorps (SYNATAC), Lyon, France
| | - Virginie Desestret
- Service de neuro-ophtalmologie et neuro-cognition (A.M., A.V., C.T., V.D.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; IMPACT-Integrative, Multisensory (L.P., A.V., C.T.), Perception, Action and Cognition Team, Centre de recherche des Neurosciences de Lyon (CRNL); Université Claude Bernard Lyon 1 (A.V., B.J., J.H., C.T., V.D.); Centre de référence français des syndromes paranéoplasiques (B.J., J.H.), Hospices Civils de Lyon, hôpital neurologique Pierre Wertheimer; and Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310 (B.J., J.H., V.D.), équipe synaptopathies et anticorps (SYNATAC), Lyon, France
| |
Collapse
|
12
|
Nadjar Y, Hütter-Moncada AL, Latour P, Ayrignac X, Kaphan E, Tranchant C, Cintas P, Degardin A, Goizet C, Laurencin C, Martzolff L, Tilikete C, Anheim M, Audoin B, Deramecourt V, De Gaillarbois TD, Roze E, Lamari F, Vanier MT, Héron B. Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect. Orphanet J Rare Dis 2018; 13:175. [PMID: 30285904 PMCID: PMC6167825 DOI: 10.1186/s13023-018-0913-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Accepted: 09/12/2018] [Indexed: 12/18/2022] Open
Abstract
Background Niemann-Pick disease type C (NP-C) is a neurodegenerative lysosomal lipid storage disease caused by autosomal recessive mutations in the NPC1 or NPC2 genes. The clinical presentation and evolution of NP-C and the effect of miglustat treatment are described in the largest cohort of patients with adolescent/adult-onset NP-C studied to date. Methods Observational study based on clinical chart data from adult patients with NP-C (> 18 year old) diagnosed in France between 1990 and 2015. Retrospective data from patients at diagnosis, onset of miglustat therapy (if applicable), and last follow up were analysed. Results In France, patients with an adolescent-adult neurological form constituted approximately 25% of all NP-C cases diagnosed during the study period. Forty-seven patients (46 with NP-C1 and one with NP-C2; 53% female) were included. Mean ± SD (range) ages at neurological onset and diagnosis were 23.9 ± 12.5 (8–56) years and 34 ± 13.5 (15–65) years, respectively. At presentation, patients mainly had 1) impaired gait due to cerebellar ataxia and/or dystonia, 2) and/or cognitive/behavioural manifestations, 3) and/or psychotic signs. Initially, almost half of patients had only one of the above three neuro-psychiatric manifestations. Vertical supranuclear gaze palsy, usually occurring without patient complaint, was only detected on careful clinical examination and was recorded in most patients (93%) at the time of diagnosis, several years after neurological onset. Thirty-seven patients (79%) received miglustat, among whom seventeen (46%) continued beyond 2 years (at last follow up) to a maximum of 9.8 years. Eight patients (22%) discontinued treatment early due to side effects (n = 3) or perceived lack of efficacy (n = 5).Miglustat treatment duration correlated significantly with reduced neurological worsening (p < 0.001). Treatment for≥2 years was associated with improved patient survival (p = 0.029). Good responses to miglustat were associated with less severe neurological disability at the start of miglustat treatment (p = 0.02). Conclusion The proportion of adolescent/adult-onset NP-C cases diagnosed in France increased 2.5-fold since 2009 compared with the 2000–2008 period due to improved awareness. Adolescent/adult-onset NP-C frequently presented initially with a non-specific isolated neuro-psychiatric manifestation (motor, cognitive or psychotic). Patients with less severe neurological disability responded better to miglustat therapy. Electronic supplementary material The online version of this article (10.1186/s13023-018-0913-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yann Nadjar
- Department of Neurology, Reference Center for Lysosomal Diseases (CRLM), UF Neuro-Genetics and Metabolism, Hôpital Pitié-Salpêtrière, 47-87, Boulevard de l'Hôpital, 75013, Paris, France.
| | | | - Philippe Latour
- Neurologic/Cardiologic Diseases Unit, Lyon East Biochemistry/Molecular Biology Department, CBPE,Hospices Civils de Lyon, Lyon, France
| | - Xavier Ayrignac
- Department of Neurology, Montpellier CHU, Gui De Chauliac Hospital, Montpellier, France
| | - Elsa Kaphan
- Clinical Neurosciences, Timone CHU, Marseille Hospital, Marseille, France
| | - Christine Tranchant
- Department of Neurology, Hautepierre Hospital, Strasbourg, France.,Institute of Genetics and Molecular and Cellular Biology (IGBMC), INSERM-U964, Strasbourg University, Illkirch, France.,Strasbourg Federation of Translational Medicine (FMTS), Strasbourg University, Strasbourg, France
| | - Pascal Cintas
- Reference Centre for Neuromuscular Pathologies, Toulouse CHU, Pierre Paul Riquet Hospital, Toulouse, France
| | - Adrian Degardin
- Department of Neurology and Movement Disorders, Roger Salengro Hospital, Lille, France
| | - Cyril Goizet
- Centre de Référence Neurogénétique, Service de Génétique, Hôpital Pellegrin, University Hospital of Bordeaux and Laboratoire MRGM, INSERM U1211, University of Bordeaux, Bordeaux, France
| | - Chloe Laurencin
- Department of Neurology, Pierre Wertheimer Neurology Hospital, Lyon, France
| | - Lionel Martzolff
- Department of Internal Medicine, Hôpital Emile Muller, Mulhouse and South Alsace Regional Hospital Group, Mulhouse, France
| | - Caroline Tilikete
- Hospices Civils de Lyon, Neuro-Ophthalmology and Neurocognition, Hôpital Neurologique Pierre Wertheimer, Lyon I University, and CRNL INSERM U1028 CNRS UMR5292, ImpAct Team, F-69676, Bron, France
| | - Mathieu Anheim
- Department of Neurology, Hautepierre Hospital, Strasbourg, France.,Institute of Genetics and Molecular and Cellular Biology (IGBMC), INSERM-U964, Strasbourg University, Illkirch, France.,Strasbourg Federation of Translational Medicine (FMTS), Strasbourg University, Strasbourg, France
| | - Bertrand Audoin
- CRMBM UMR 7339, CNRS, Aix-Marseille Université, Marseille, France.,APHM, Hôpital de la Timone, Clinical Neurosciences, Department of Neurology, Marseille, France
| | - Vincent Deramecourt
- University of Lille, INSERM, CHU Lille, Degenerative & Vascular Cognitive Disorders, Lille, France
| | | | - Emmanuel Roze
- Department of Neurology, Reference Center for Lysosomal Diseases (CRLM), UF Neuro-Genetics and Metabolism, Hôpital Pitié-Salpêtrière, 47-87, Boulevard de l'Hôpital, 75013, Paris, France.,Sorbonne UPMC University, INSERM U 1127, and the Institute for the Brain and Spinal Cord, Paris, France
| | - Foudil Lamari
- Department Metabolic Biochemistry and GRC 13-Neurometabolism-UPMC, Hôpital Pitié-Salpêtrière, Paris, France
| | - Marie T Vanier
- INSERM U820, Lyon, France.,Laboratoire Gillet-Mérieux, CBPE, Hospices Civils de Lyon, Lyon, France
| | - Bénédicte Héron
- Reference Centre for Lysosomal Diseases (CRML), Department of Pediatric Neurology, and Sorbonne Université, GRC n°19, Pathologies Congénitales du Cervelet-LeucoDystrophies, AP-HP, Hôpital Armand Trousseau, F-75012, Paris, France
| |
Collapse
|
13
|
Román LS, Menon BK, Blasco J, Hernández-Pérez M, Dávalos A, Majoie CBLM, Campbell BCV, Guillemin F, Lingsma H, Anxionnat R, Epstein J, Saver JL, Marquering H, Wong JH, Lopes D, Reimann G, Desal H, Dippel DWJ, Coutts S, du Mesnil de Rochemont R, Yavagal D, Ferre JC, Roos YBWEM, Liebeskind DS, Lenthall R, Molina C, Al Ajlan FS, Reddy V, Dowlatshahi D, Sourour NA, Oppenheim C, Mitha AP, Davis SM, Weimar C, van Oostenbrugge RJ, Cobo E, Kleinig TJ, Donnan GA, van der Lugt A, Demchuk AM, Berkhemer OA, Boers AMM, Ford GA, Muir KW, Brown BS, Jovin T, van Zwam WH, Mitchell PJ, Hill MD, White P, Bracard S, Goyal M, Berkhemer OA, Fransen PSS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJH, van Walderveen MAA, Staals J, Hofmeijer J, van Oostayen JA, Lycklama à Nijeholt GJ, Boiten J, Brouwer PA, Emmer BJ, de Bruijn SF, van Dijk LC, Kappelle J, Lo RH, van Dijk EJ, de Vries J, de Kort PL, van Rooij WJJ, van den Berg JS, van Hasselt BA, Aerden LA, Dallinga RJ, Visser MC, Bot JC, Vroomen PC, Eshghi O, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gerrits DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach Z, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, Zech M, Kowarik M, Seifert C, Schwaiger B, Puri A, Hou S, Wakhloo A, Moonis M, Henniger N, Goddeau R, van den Berg R, Massari F, Minaeian A, Lozano JD, Ramzan M, Stout C, Patel A, Tunguturi A, Onteddu S, Carandang R, Howk M, Koudstaal PJ, Ribó M, Sanjuan E, Rubiera M, Pagola J, Flores A, Muchada M, Meler P, Huerga E, Gelabert S, Coscojuela P, van Zwam WH, Tomasello A, Rodriguez D, Santamarina E, Maisterra O, Boned S, Seró L, Rovira A, Molina CA, Millán M, Muñoz L, Roos YB, Pérez de la Ossa N, Gomis M, Dorado L, López-Cancio E, Palomeras E, Munuera J, García Bermejo P, Remollo S, Castaño C, García-Sort R, van der Lugt A, Cuadras P, Puyalto P, Hernández-Pérez M, Jiménez M, Martínez-Piñeiro A, Lucente G, Dávalos A, Chamorro A, Urra X, Obach V, van Oostenbrugge RJ, Cervera A, Amaro S, Llull L, Codas J, Balasa M, Navarro J, Ariño H, Aceituno A, Rudilosso S, Renu A, Majoie CB, Macho JM, San Roman L, Blasco J, López A, Macías N, Cardona P, Quesada H, Rubio F, Cano L, Lara B, Dippel DW, de Miquel MA, Aja L, Serena J, Cobo E, Albers GW, Lees KR, Arenillas J, Roberts R, Minhas P, Al-Ajlan F, Brown MM, Salluzzi M, Zimmel L, Patel S, Eesa M, Martí-Fàbregas J, Jankowitz B, Serena J, Salvat-Plana M, López-Cancio E, Bracard S, Liebig T, Ducrocq X, Anxionnat R, Baillot PA, Barbier C, Derelle AL, Lacour JC, Richard S, Samson Y, Sourour N, Baronnet-Chauvet F, Stijnen T, Clarencon F, Crozier S, Deltour S, Di Maria F, Le Bouc R, Leger A, Mutlu G, Rosso C, Szatmary Z, Yger M, Andersson T, Zavanone C, Bakchine S, Pierot L, Caucheteux N, Estrade L, Kadziolka K, Leautaud A, Renkes C, Serre I, Desal H, Mattle H, Guillon B, Boutoleau-Bretonniere C, Daumas-Duport B, De Gaalon S, Derkinderen P, Evain S, Herisson F, Laplaud DA, Lebouvier T, Lintia-Gaultier A, Wahlgren N, Pouclet-Courtemanche H, Rouaud T, Rouaud Jaffrenou V, Schunck A, Sevin-Allouet M, Toulgoat F, Wiertlewski S, Gauvrit JY, Ronziere T, Cahagne V, van der Heijden E, Ferre JC, Pinel JF, Raoult H, Mas JL, Meder JF, Al Najjar-Carpentier AA, Birchenall J, Bodiguel E, Calvet D, Domigo V, Ghannouti N, Godon-Hardy S, Guiraud V, Lamy C, Majhadi L, Morin L, Naggara O, Trystram D, Turc G, Berge J, Sibon I, Fleitour N, Menegon P, Barreau X, Rouanet F, Debruxelles S, Kazadi A, Renou P, Fleury O, Pasco-Papon A, Dubas F, Caroff J, Hooijenga I, Godard Ducceschi S, Hamon MA, Lecluse A, Marc G, Giroud M, Ricolfi F, Bejot Y, Chavent A, Gentil A, Kazemi A, Puppels C, Osseby GV, Voguet C, Mahagne MH, Sedat J, Chau Y, Suissa L, Lachaud S, Houdart E, Stapf C, Buffon Porcher F, Pellikaan W, Chabriat H, Guedin P, Herve D, Jouvent E, Mawet J, Saint-Maurice JP, Schneble HM, Turjman F, Nighoghossian N, Berhoune NN, Geerling A, Bouhour F, Cho TH, Derex L, Felix S, Gervais-Bernard H, Gory B, Manera L, Mechtouff L, Ritzenthaler T, Riva R, Lindl-Velema A, Salaris Silvio F, Tilikete C, Blanc R, Obadia M, Bartolini MB, Gueguen A, Piotin M, Pistocchi S, Redjem H, Drouineau J, van Vemde G, Neau JP, Godeneche G, Lamy M, Marsac E, Velasco S, Clavelou P, Chabert E, Bourgois N, Cornut-Chauvinc C, Ferrier A, de Ridder A, Gabrillargues J, Jean B, Marques AR, Vitello N, Detante O, Barbieux M, Boubagra K, Favre Wiki I, Garambois K, Tahon F, Greebe P, Ashok V, Voguet C, Coskun O, Guedin P, Rodesch G, Lapergue B, Bourdain F, Evrard S, Graveleau P, Decroix JP, de Bont-Stikkelbroeck J, Wang A, Sellal F, Ahle G, Carelli G, Dugay MH, Gaultier C, Lebedinsky AP, Lita L, Musacchio RM, Renglewicz-Destuynder C, de Meris J, Tournade A, Vuillemet F, Montoro FM, Mounayer C, Faugeras F, Gimenez L, Labach C, Lautrette G, Denier C, Saliou G, Janssen K, Chassin O, Dussaule C, Melki E, Ozanne A, Puccinelli F, Sachet M, Sarov M, Bonneville JF, Moulin T, Biondi A, Struijk W, De Bustos Medeiros E, Vuillier F, Courtheoux P, Viader F, Apoil-Brissard M, Bataille M, Bonnet AL, Cogez J, Kazemi A, Touze E, Licher S, Leclerc X, Leys D, Aggour M, Aguettaz P, Bodenant M, Cordonnier C, Deplanque D, Girot M, Henon H, Kalsoum E, Boodt N, Lucas C, Pruvo JP, Zuniga P, Bonafé A, Arquizan C, Costalat V, Machi P, Mourand I, Riquelme C, Bounolleau P, Ros A, Arteaga C, Faivre A, Bintner M, Tournebize P, Charlin C, Darcel F, Gauthier-Lasalarie P, Jeremenko M, Mouton S, Zerlauth JB, Venema E, Lamy C, Hervé D, Hassan H, Gaston A, Barral FG, Garnier P, Beaujeux R, Wolff V, Herbreteau D, Debiais S, Slokkers I, Murray A, Ford G, Muir KW, White P, Brown MM, Clifton A, Freeman J, Ford I, Markus H, Wardlaw J, Ganpat RJ, Lees KR, Molyneux A, Robinson T, Lewis S, Norrie J, Robertson F, Perry R, Dixit A, Cloud G, Clifton A, Mulder M, Madigan J, Roffe C, Nayak S, Lobotesis K, Smith C, Herwadkar A, Kandasamy N, Goddard T, Bamford J, Subramanian G, Saiedie N, Lenthall R, Littleton E, Lamin S, Storey K, Ghatala R, Banaras A, Aeron-Thomas J, Hazel B, Maguire H, Veraque E, Heshmatollah A, Harrison L, Keshvara R, Cunningham J, Schipperen S, Vinken S, van Boxtel T, Koets J, Boers M, Santos E, Borst J, Jansen I, Kappelhof M, Lucas M, Geuskens R, Barros RS, Dobbe R, Csizmadia M, Hill MD, Goyal M, Demchuk AM, Menon BK, Eesa M, Ryckborst KJ, Wright MR, Kamal NR, Andersen L, Randhawa PA, Stewart T, Patil S, Minhas P, Almekhlafi M, Mishra S, Clement F, Sajobi T, Shuaib A, Montanera WJ, Roy D, Silver FL, Jovin TG, Frei DF, Sapkota B, Rempel JL, Thornton J, Williams D, Tampieri D, Poppe AY, Dowlatshahi D, Wong JH, Mitha AP, Subramaniam S, Hull G, Lowerison MW, Sajobi T, Salluzzi M, Wright MR, Maxwell M, Lacusta S, Drupals E, Armitage K, Barber PA, Smith EE, Morrish WF, Coutts SB, Derdeyn C, Demaerschalk B, Yavagal D, Martin R, Brant R, Yu Y, Willinsky RA, Montanera WJ, Weill A, Kenney C, Aram H, Stewart T, Stys PK, Watson TW, Klein G, Pearson D, Couillard P, Trivedi A, Singh D, Klourfeld E, Imoukhuede O, Nikneshan D, Blayney S, Reddy R, Choi P, Horton M, Musuka T, Dubuc V, Field TS, Desai J, Adatia S, Alseraya A, Nambiar V, van Dijk R, Wong JH, Mitha AP, Morrish WF, Eesa M, Newcommon NJ, Shuaib A, Schwindt B, Butcher KS, Jeerakathil T, Buck B, Khan K, Naik SS, Emery DJ, Owen RJ, Kotylak TB, Ashforth RA, Yeo TA, McNally D, Siddiqui M, Saqqur M, Hussain D, Kalashyan H, Manosalva A, Kate M, Gioia L, Hasan S, Mohammad A, Muratoglu M, Williams D, Thornton J, Cullen A, Brennan P, O'Hare A, Looby S, Hyland D, Duff S, McCusker M, Hallinan B, Lee S, McCormack J, Moore A, O'Connor M, Donegan C, Brewer L, Martin A, Murphy S, O'Rourke K, Smyth S, Kelly P, Lynch T, Daly T, O'Brien P, O'Driscoll A, Martin M, Daly T, Collins R, Coughlan T, McCabe D, Murphy S, O'Neill D, Mulroy M, Lynch O, Walsh T, O'Donnell M, Galvin T, Harbison J, McElwaine P, Mulpeter K, McLoughlin C, Reardon M, Harkin E, Dolan E, Watts M, Cunningham N, Fallon C, Gallagher S, Cotter P, Crowe M, Doyle R, Noone I, Lapierre M, Coté VA, Lanthier S, Odier C, Durocher A, Raymond J, Weill A, Daneault N, Deschaintre Y, Jankowitz B, Baxendell L, Massaro L, Jackson-Graves C, Decesare S, Porter P, Armbruster K, Adams A, Billigan J, Oakley J, Ducruet A, Jadhav A, Giurgiutiu DV, Aghaebrahim A, Reddy V, Hammer M, Starr M, Totoraitis V, Wechsler L, Streib S, Rangaraju S, Campbell D, Rocha M, Gulati D, Silver FL, Krings T, Kalman L, Cayley A, Williams J, Stewart T, Wiegner R, Casaubon LK, Jaigobin C, del Campo JM, Elamin E, Schaafsma JD, Willinsky RA, Agid R, Farb R, ter Brugge K, Sapkoda BL, Baxter BW, Barton K, Knox A, Porter A, Sirelkhatim A, Devlin T, Dellinger C, Pitiyanuvath N, Patterson J, Nichols J, Quarfordt S, Calvert J, Hawk H, Fanale C, Frei DF, Bitner A, Novak A, Huddle D, Bellon R, Loy D, Wagner J, Chang I, Lampe E, Spencer B, Pratt R, Bartt R, Shine S, Dooley G, Nguyen T, Whaley M, McCarthy K, Teitelbaum J, Tampieri D, Poon W, Campbell N, Cortes M, Dowlatshahi D, Lum C, Shamloul R, Robert S, Stotts G, Shamy M, Steffenhagen N, Blacquiere D, Hogan M, AlHazzaa M, Basir G, Lesiuk H, Iancu D, Santos M, Choe H, Weisman DC, Jonczak K, Blue-Schaller A, Shah Q, MacKenzie L, Klein B, Kulandaivel K, Kozak O, Gzesh DJ, Harris LJ, Khoury JS, Mandzia J, Pelz D, Crann S, Fleming L, Hesser K, Beauchamp B, Amato-Marzialli B, Boulton M, Lopez-Ojeda P, Sharma M, Lownie S, Chan R, Swartz R, Howard P, Golob D, Gladstone D, Boyle K, Boulos M, Hopyan J, Yang V, Da Costa L, Holmstedt CA, Turk AS, Navarro R, Jauch E, Ozark S, Turner R, Phillips S, Shankar J, Jarrett J, Gubitz G, Maloney W, Vandorpe R, Schmidt M, Heidenreich J, Hunter G, Kelly M, Whelan R, Peeling L, Burns PA, Hunter A, Wiggam I, Kerr E, Watt M, Fulton A, Gordon P, Rennie I, Flynn P, Smyth G, O'Leary S, Gentile N, Linares G, McNelis P, Erkmen K, Katz P, Azizi A, Weaver M, Jungreis C, Faro S, Shah P, Reimer H, Kalugdan V, Saposnik G, Bharatha A, Li Y, Kostyrko P, Santos M, Marotta T, Montanera W, Sarma D, Selchen D, Spears J, Heo JH, Jeong K, Kim DJ, Kim BM, Kim YD, Song D, Lee KJ, Yoo J, Bang OY, Rho S, Lee J, Jeon P, Kim KH, Cha J, Kim SJ, Ryoo S, Lee MJ, Sohn SI, Kim CH, Ryu HG, Hong JH, Chang HW, Lee CY, Rha J, Davis SM, Donnan GA, Campbell BCV, Mitchell PJ, Churilov L, Yan B, Dowling R, Yassi N, Oxley TJ, Wu TY, Silver G, McDonald A, McCoy R, Kleinig TJ, Scroop R, Dewey HM, Simpson M, Brooks M, Coulton B, Krause M, Harrington TJ, Steinfort B, Faulder K, Priglinger M, Day S, Phan T, Chong W, Holt M, Chandra RV, Ma H, Young D, Wong K, Wijeratne T, Tu H, Mackay E, Celestino S, Bladin CF, Loh PS, Gilligan A, Ross Z, Coote S, Frost T, Parsons MW, Miteff F, Levi CR, Ang T, Spratt N, Kaauwai L, Badve M, Rice H, de Villiers L, Barber PA, McGuinness B, Hope A, Moriarty M, Bennett P, Wong A, Coulthard A, Lee A, Jannes J, Field D, Sharma G, Salinas S, Cowley E, Snow B, Kolbe J, Stark R, King J, Macdonnell R, Attia J, D'Este C, Saver JL, Goyal M, Diener HC, Levy EI, Bonafé A, Mendes Pereira V, Jahan R, Albers GW, Cognard C, Cohen DJ, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, von Kummer R, Smith W, Turjman F, Hamilton S, Chiacchierini R, Amar A, Sanossian N, Loh Y, Devlin T, Baxter B, Hawk H, Sapkota B, Quarfordt S, Sirelkhatim A, Dellinger C, Barton K, Reddy VK, Ducruet A, Jadhav A, Horev A, Giurgiutiu DV, Totoraitis V, Hammer M, Jankowitz B, Wechsler L, Rocha M, Gulati D, Campbell D, Star M, Baxendell L, Oakley J, Siddiqui A, Hopkins LN, Snyder K, Sawyer R, Hall S, Costalat V, Riquelme C, Machi P, Omer E, Arquizan C, Mourand I, Charif M, Ayrignac X, Menjot de Champfleur N, Leboucq N, Gascou G, Moynier M, du Mesnil de Rochemont R, Singer O, Berkefeld J, Foerch C, Lorenz M, Pfeilschifer W, Hattingen E, Wagner M, You SJ, Lescher S, Braun H, Dehkharghani S, Belagaje SR, Anderson A, Lima A, Obideen M, Haussen D, Dharia R, Frankel M, Patel V, Owada K, Saad A, Amerson L, Horn C, Doppelheuer S, Schindler K, Lopes DK, Chen M, Moftakhar R, Anton C, Smreczak M, Carpenter JS, Boo S, Rai A, Roberts T, Tarabishy A, Gutmann L, Brooks C, Brick J, Domico J, Reimann G, Hinrichs K, Becker M, Heiss E, Selle C, Witteler A, Al-Boutros S, Danch MJ, Ranft A, Rohde S, Burg K, Weimar C, Zegarac V, Hartmann C, Schlamann M, Göricke S, Ringlestein A, Wanke I, Mönninghoff C, Dietzold M, Budzik R, Davis T, Eubank G, Hicks WJ, Pema P, Vora N, Mejilla J, Taylor M, Clark W, Rontal A, Fields J, Peterson B, Nesbit G, Lutsep H, Bozorgchami H, Priest R, Ologuntoye O, Barnwell S, Dogan A, Herrick K, Takahasi C, Beadell N, Brown B, Jamieson S, Hussain MS, Russman A, Hui F, Wisco D, Uchino K, Khawaja Z, Katzan I, Toth G, Cheng-Ching E, Bain M, Man S, Farrag A, George P, John S, Shankar L, Drofa A, Dahlgren R, Bauer A, Itreat A, Taqui A, Cerejo R, Richmond A, Ringleb P, Bendszus M, Möhlenbruch M, Reiff T, Amiri H, Purrucker J, Herweh C, Pham M, Menn O, Ludwig I, Acosta I, Villar C, Morgan W, Sombutmai C, Hellinger F, Allen E, Bellew M, Gandhi R, Bonwit E, Aly J, Ecker RD, Seder D, Morris J, Skaletsky M, Belden J, Baker C, Connolly LS, Papanagiotou P, Roth C, Kastrup A, Politi M, Brunner F, Alexandrou M, Merdivan H, Ramsey C, Given II C, Renfrow S, Deshmukh V, Sasadeusz K, Vincent F, Thiesing JT, Putnam J, Bhatt A, Kansara A, Caceves D, Lowenkopf T, Yanase L, Zurasky J, Dancer S, Freeman B, Scheibe-Mirek T, Robison J, Rontal A, Roll J, Clark D, Rodriguez M, Fitzsimmons BFM, Zaidat O, Lynch JR, Lazzaro M, Larson T, Padmore L, Das E, Farrow-Schmidt A, Hassan A, Tekle W, Cate C, Jansen O, Cnyrim C, Wodarg F, Wiese C, Binder A, Riedel C, Rohr A, Lang N, Laufs H, Krieter S, Remonda L, Diepers M, Añon J, Nedeltchev K, Kahles T, Biethahn S, Lindner M, Chang V, Gächter C, Esperon C, Guglielmetti M, Arenillas Lara JF, Martínez Galdámez M, Calleja Sanz AI, Cortijo Garcia E, Garcia Bermejo P, Perez S, Mulero Carrillo P, Crespo Vallejo E, Ruiz Piñero M, Lopez Mesonero L, Reyes Muñoz FJ, Brekenfeld C, Buhk JH, Krützelmann A, Thomalla G, Cheng B, Beck C, Hoppe J, Goebell E, Holst B, Grzyska U, Wortmann G, Starkman S, Duckwiler G, Jahan R, Rao N, Sheth S, Ng K, Noorian A, Szeder V, Nour M, McManus M, Huang J, Tarpley J, Tateshima S, Gonzalez N, Ali L, Liebeskind D, Hinman J, Calderon-Arnulphi M, Liang C, Guzy J, Koch S, DeSousa K, Gordon-Perue G, Haussen D, Elhammady M, Peterson E, Pandey V, Dharmadhikari S, Khandelwal P, Malik A, Pafford R, Gonzalez P, Ramdas K, Andersen G, Damgaard D, Von Weitzel-Mudersbach P, Simonsen C, Ruiz de Morales Ayudarte N, Poulsen M, Sørensen L, Karabegovich S, Hjørringgaard M, Hjort N, Harbo T, Sørensen K, Deshaies E, Padalino D, Swarnkar A, Latorre JG, Elnour E, El-Zammar Z, Villwock M, Farid H, Balgude A, Cross L, Hansen K, Holtmannspötter M, Kondziella D, Hoejgaard J, Taudorf S, Soendergaard H, Wagner A, Cronquist M, Stavngaard T, Cortsen M, Krarup LH, Hyldal T, Haring HP, Guggenberger S, Hamberger M, Trenkler J, Sonnberger M, Nussbaumer K, Dominger C, Bach E, Jagadeesan BD, Taylor R, Kim J, Shea K, Tummala R, Zacharatos H, Sandhu D, Ezzeddine M, Grande A, Hildebrandt D, Miller K, Scherber J, Hendrickson A, Jumaa M, Zaidi S, Hendrickson T, Snyder V, Killer-Oberpfalzer M, Mutzenbach J, Weymayr F, Broussalis E, Stadler K, Jedlitschka A, Malek A, Mueller-Kronast N, Beck P, Martin C, Summers D, Day J, Bettinger I, Holloway W, Olds K, Arkin S, Akhtar N, Boutwell C, Crandall S, Schwartzman M, Weinstein C, Brion B, Prothmann S, Kleine J, Kreiser K, Boeckh-Behrens T, Poppert H, Wunderlich S, Koch ML, Biberacher V, Huberle A, Gora-Stahlberg G, Knier B, Meindl T, Utpadel-Fischler D. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. Lancet Neurol 2018; 17:895-904. [DOI: 10.1016/s1474-4422(18)30242-4] [Citation(s) in RCA: 213] [Impact Index Per Article: 35.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Revised: 06/11/2018] [Accepted: 06/12/2018] [Indexed: 11/29/2022]
|
14
|
Holden JG, Cosnard A, Laurens B, Asselineau J, Biotti D, Cubizolle S, Dupouy S, Formaglio M, Koric L, Seassau M, Tilikete C, Vighetto A, Tison F. Prodromal Alzheimer’s Disease Demonstrates Increased Errors at a Simple and Automated Anti-Saccade Task. J Alzheimers Dis 2018; 65:1209-1223. [DOI: 10.3233/jad-180082] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- John G. Holden
- Institute for Neurodegenerative Diseases, Clinical Branch, University and University Hospital of Bordeaux, Bordeaux, France
- Department of Psychology, University of Cincinnati, OH, USA
| | - Alexandre Cosnard
- Institute for Neurodegenerative Diseases, Clinical Branch, University and University Hospital of Bordeaux, Bordeaux, France
| | - Brice Laurens
- Institute for Neurodegenerative Diseases, Clinical Branch, University and University Hospital of Bordeaux, Bordeaux, France
| | - Julien Asselineau
- Department of Public Health Bordeaux University Hospital, Clinical Epidemiology Unit, Bordeaux, France
| | - Damien Biotti
- Department of Neurocognition, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, Lyon, France
| | - Stéphanie Cubizolle
- Institute for Neurodegenerative Diseases, Clinical Branch, University and University Hospital of Bordeaux, Bordeaux, France
| | - Sandrine Dupouy
- Institute for Neurodegenerative Diseases, Clinical Branch, University and University Hospital of Bordeaux, Bordeaux, France
| | - Maıté Formaglio
- Department of Neurocognition, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, Lyon, France
| | - Lejla Koric
- Department of Neurology and Neuropsychology University Hospital la Timone, Marseille, France
| | | | - Caroline Tilikete
- Department of Neurocognition, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, Lyon, France
| | - Alain Vighetto
- Department of Neurocognition, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, Lyon, France
| | - François Tison
- Institute for Neurodegenerative Diseases, Clinical Branch, University and University Hospital of Bordeaux, Bordeaux, France
| |
Collapse
|
15
|
Chabanat E, Jacquin-Courtois S, Havé L, Kihoulou C, Tilikete C, Mauguière F, Rheims S, Rossetti Y. Can you guess the colour of this moving object? A dissociation between colour and motion in blindsight. Neuropsychologia 2018; 128:204-208. [PMID: 30102905 DOI: 10.1016/j.neuropsychologia.2018.08.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Revised: 06/01/2018] [Accepted: 08/08/2018] [Indexed: 10/28/2022]
Abstract
Blindsight has been primarily and extensively studied by Lawrence Weiskrantz. Residual visual abilities following a hemispheric lesion leading to homonymous hemianopia encompass a variety of visual-perceptual and visuo-motor functions. Attention blindsight produces the more salient subjective experiences, especially for motion (Riddoch phenomenon). Action blindsight illustrates visuo-motor abilities despite the patients' feeling that they produce random movements. Perception blindsight seems to be the weakest residual function observed in blindsight, e.g. for wavelength sensitivity. Discriminating motion produced by isoluminant colours does not give rise to blindsight for motion but the outcome of the reciprocal test is not known. Here we tested whether moving stimuli could give rise to colour discrimination in a patient with homonymous hemianopia. It was found that even though the patient exhibited nearly perfect performances for motion direction discrimination his colour discrimination for the same moving stimulus remained at chance level. It is concluded that easily discriminated moving stimuli do not give rise to colour discrimination and implications for the 3 levels of blindsight taxonomy are discussed.
Collapse
Affiliation(s)
- E Chabanat
- Inserm UMR-S 1028, CNRS UMR 5292, ImpAct, Centre de Recherche en Neurosciences de Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, France.
| | - S Jacquin-Courtois
- Inserm UMR-S 1028, CNRS UMR 5292, ImpAct, Centre de Recherche en Neurosciences de Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, France; Service de rééducation neurologique, Pavillon Bourret, Hôpital Henry-Gabrielle, Hospices Civils de Lyon, 20, route de Vourles, Saint-Genis-Laval, France; Plate-forme 'Mouvement et Handicap', Hôpital Henry-Gabrielle et Hôpital Neurologique Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 20, route de Vourles, Saint-Genis-Laval, France.
| | - L Havé
- Inserm UMR-S 1028, CNRS UMR 5292, ImpAct, Centre de Recherche en Neurosciences de Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, France.
| | - C Kihoulou
- Inserm UMR-S 1028, CNRS UMR 5292, ImpAct, Centre de Recherche en Neurosciences de Lyon, France
| | - C Tilikete
- Inserm UMR-S 1028, CNRS UMR 5292, ImpAct, Centre de Recherche en Neurosciences de Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, France; Service de Neuro-Cognition et Neuro-Ophtalmologie, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 59 boulevard Pinel, 69677 Bron Cedex, France.
| | - F Mauguière
- Université de Lyon, Université Claude Bernard Lyon 1, France; Département de Neurologie Fonctionnelle et Epileptologie, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France; Inserm UMR-S 1028, CNRS UMR 5292, NeuroPain, Centre de Recherche en Neurosciences de Lyon, France.
| | - S Rheims
- Université de Lyon, Université Claude Bernard Lyon 1, France; Département de Neurologie Fonctionnelle et Epileptologie, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France; Inserm UMR-S 1028, CNRS UMR 5292, TIGER, Centre de Recherche en Neurosciences de Lyon, France.
| | - Y Rossetti
- Inserm UMR-S 1028, CNRS UMR 5292, ImpAct, Centre de Recherche en Neurosciences de Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, France; Service de rééducation neurologique, Pavillon Bourret, Hôpital Henry-Gabrielle, Hospices Civils de Lyon, 20, route de Vourles, Saint-Genis-Laval, France; Plate-forme 'Mouvement et Handicap', Hôpital Henry-Gabrielle et Hôpital Neurologique Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 20, route de Vourles, Saint-Genis-Laval, France.
| |
Collapse
|
16
|
Hermann R, Ionescu EC, Dumas O, Tringali S, Truy E, Tilikete C. Bilateral Vestibulopathy: Vestibular Function, Dynamic Visual Acuity and Functional Impact. Front Neurol 2018; 9:555. [PMID: 30042725 PMCID: PMC6048872 DOI: 10.3389/fneur.2018.00555] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 06/20/2018] [Indexed: 11/16/2022] Open
Abstract
Introduction: Patients suffering from bilateral vestibular hypofunction (BVH) often experience ataxia as well as visual instability. Even though progress has been made in vestibular testing, insights regarding vestibular deficit in BVH remain incomplete since no method allows evaluation of frequency ranges of vestibular sensors in a continuous way. The aim of our study was to give a detailed description of the level of vestibular deficit in different ranges of vestibular stimulation and an exhaustive evaluation of the functional impact including dynamic visual acuity (DVA) in a cohort of BVH patients in different etiologies. Methods: We prospectively included 20 patients with chronic BVH. All patients underwent clinical evaluation and functional assessment including evaluation of their symptoms related to BVH, quality of life questionnaire and DVA in the horizontal and vertical plane. Patients underwent vestibulo-ocular reflex (VOR) testing using rotatory chair, caloric stimulation and video head impulse (vHIT) in the plane of the 6 canals, and cervical and ocular Vestibular evoked myogenic potentials. Results: Mean rotatory VOR gain was 0.07 (SD = 0.07). Mean rotatory VOR gain during vHIT for the lateral, anterior and posterior canals was respectively < 0.28, < 0.34, and < 0.20. Mean loss of DVA in the 4 directions was >0.30 LogMAR. In our population fall frequency was significantly higher in patients with lower UniPedal Stance Test (UPST), higher Dizziness Handicap Inventory and Ataxia Numeric Scale (ANS) scores, as well as greater loss of upwards DVA. Patients with ototoxic BVH had a significantly higher residual VOR gain during vHIT in the anterior canal plane and lower DHI than other patients. In the general population anterior canal function was significantly higher than lateral or posterior canal function. Conclusions: This study gives extensive descriptive results of residual vestibular function, DVA and quality of life in a population of patients suffering from severe BVH. UPST and ANS are good indicators for fall risk in case of BVH. Gentamicin induced BVH seems to have a lesser impact on quality of life than other etiologies.Anterior semi-circular canal function seems less deteriorated than lateral and posterior function.
Collapse
Affiliation(s)
- Ruben Hermann
- ENT and Cervico-Facial Surgery Department, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.,INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, Equipe IMPACT, Lyon, France.,University Lyon 1, Lyon, France
| | - Eugen C Ionescu
- Department of Audiology and Otoneurological Evaluation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Olivier Dumas
- Société Française de Kinésithérapie Vestibulaire, Lyon, France
| | - Stephane Tringali
- University Lyon 1, Lyon, France.,Department of Otology and Otoneurology, Hôpital Lyon Sud, Hospice Civils de Lyon, Lyon, France
| | - Eric Truy
- ENT and Cervico-Facial Surgery Department, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.,INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, Equipe IMPACT, Lyon, France.,University Lyon 1, Lyon, France
| | - Caroline Tilikete
- INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, Equipe IMPACT, Lyon, France.,University Lyon 1, Lyon, France.,Neuro-Ophthalmology Unit, Hopital Neurologique et Neurochirurgical P Wertheimer, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
17
|
Heidelberg D, Ronsin S, Bonneville F, Hannoun S, Tilikete C, Cotton F. Main inherited neurodegenerative cerebellar ataxias, how to recognize them using magnetic resonance imaging? J Neuroradiol 2018; 45:265-275. [PMID: 29920348 DOI: 10.1016/j.neurad.2018.05.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2017] [Revised: 05/09/2018] [Accepted: 05/28/2018] [Indexed: 12/12/2022]
Abstract
Ataxia is a neurodegenerative disease resulting from brainstem, cerebellar, and/or spinocerebellar tracts impairments. Symptoms onset could vary widely from childhood to late-adulthood. Autosomal cerebellar ataxias are considered as one of the most complex group in neurogenetics. In addition to their genetic heterogeneity, there is an important phenotypic variability in the expression of cerebellar impairment, complicating the genetic mutation research. A pattern recognition approach using brain MRI measures of atrophy, hyperintensities and iron-induced hypointensity of the dentate nuclei, could be therefore helpful in guiding genetic research. This review will discuss a pattern recognition approach that, associated with the age at disease onset, and clinical manifestations, may help neuroradiologists differentiate the most frequent profiles of ataxia.
Collapse
Affiliation(s)
- D Heidelberg
- Faculty of Medicine, Claude-Bernard Lyon 1 University, 69000 Lyon, France; Service de radiologie and Laboratoire d'anatomie de Rockefeller, centre hospitalier Lyon Sud, hospices civils de Lyon, 69000 Lyon, France
| | - S Ronsin
- Neuro-ophtalmology unit and neurology D, Neurological and Neurosurgical Hospital P. Wertheimer, Hospices Civils de Lyon, 69000 Lyon, France
| | - F Bonneville
- Service de neuroradiologie diagnostique et thérapeutique, Hôpitaux de Toulouse, Hôpital Pierre-Paul-Riquet, 31000 Toulouse, France
| | - S Hannoun
- Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, 1107, 2020 Beirut, Lebanon
| | - C Tilikete
- Faculty of Medicine, Claude-Bernard Lyon 1 University, 69000 Lyon, France; Neuro-ophtalmology unit and neurology D, Neurological and Neurosurgical Hospital P. Wertheimer, Hospices Civils de Lyon, 69000 Lyon, France; Lyon neuroscience research center, Inserm U1028, CNRS UMR5292, Impact Team, 69000 Lyon, France
| | - F Cotton
- Faculty of Medicine, Claude-Bernard Lyon 1 University, 69000 Lyon, France; Service de radiologie and Laboratoire d'anatomie de Rockefeller, centre hospitalier Lyon Sud, hospices civils de Lyon, 69000 Lyon, France; CREATIS, Inserm U1044/CNRS UMR 5220, 69000 Lyon, France.
| |
Collapse
|
18
|
Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology 2018; 90:e1858-e1869. [DOI: 10.1212/wnl.0000000000005560] [Citation(s) in RCA: 300] [Impact Index Per Article: 50.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Accepted: 02/27/2018] [Indexed: 11/15/2022] Open
Abstract
ObjectiveTo describe clinical and radiologic features associated with myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) in a large French nationwide adult cohort, to assess baseline prognostic features of MOG-Ab-associated diseases after a first acute demyelinating syndrome, and to evaluate the clinical value of MOG-Ab longitudinal analysis.MethodsClinical data were obtained from 197 MOG-Ab-positive patients ≥18 years of age. Complete imaging data were available in 108, and 54 serum samples were eligible for longitudinal evaluation. For survival analysis comparison, 169 aquaporin-4 antibody (AQP4-Ab)-positive patients from the NOMADMUS database were included.ResultsMedian age at onset was 36.46 (range 18.0–76.8) years, and patients were predominantly white (92.9%) with male:female ratio, 1.1. Clinical phenotype at onset included optic neuritis or myelitis in 90.86%, isolated brainstem or encephalopathy syndromes in 6.6%, and a combination of syndromes in 2.5%. Distinctive brain MRI findings in MOG-Ab-positive patients were thalamic and pontine lesions. Cortical and leptomeningeal lesions were found in 16.3% and 6.1%, respectively. The probability of reaching a first relapse after 2 and 5 years was 44.8% and 61.8%, respectively. MOG-Ab-positive patients were at lower risk at presentation of further clinical relapse (hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.26–0.79) compared to AQP4-Ab-positive individuals. MOG-Ab-positive individuals had a lower risk of reaching Disability Status Scale score of 3.0 (HR 0.46, 95% CI 0.22–0.94) and visual acuity of 20/100 (HR 0.23, 95% CI 0.07–0.72). Finally, MOG-Ab titers were higher at relapse than in remission (p = 0.009).ConclusionIn adults, MOG-Ab-associated disease extends beyond clinical and radiologic abnormalities in the optic nerve and spinal cord. Despite the relapsing course, the overall visual and motor outcome is better compared with AQP4-Ab-positive patients.
Collapse
|
19
|
Heidelberg D, Ronsin S, Bonneville F, Hannoun S, Tilikete C, Cotton F. Principales ataxies cérébelleuses neurodégénératives héréditaires, comment les reconnaître en IRM ? J Neuroradiol 2018. [DOI: 10.1016/j.neurad.2018.01.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
20
|
Blini E, Tilikete C, Farnè A, Hadj-Bouziane F. Probing the role of the vestibular system in motivation and reward-based attention. Cortex 2018; 103:82-99. [PMID: 29574253 PMCID: PMC6002611 DOI: 10.1016/j.cortex.2018.02.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Revised: 02/07/2018] [Accepted: 02/07/2018] [Indexed: 01/31/2023]
Abstract
The vestibular system has widespread connections in the central nervous system. Several activation loci following vestibular stimulations have been notably reported in deep, limbic areas that are otherwise difficult to reach and modulate in healthy subjects. Following preliminary evidence, suggesting that such stimulations might affect mood and affective processing, we wondered whether the vestibular system is also involved in motivation. Evolutionary accounts suggest that visuo-vestibular mismatches might have a role in preventing the search for and exploitation of goods that previously resulted in aversive reactions, as they would be a fine warning signal which follows the contact with or ingestion of noxious neurotoxins. The first question was thus whether vestibular stimulation alters sensitivity to reward. Secondly, we sought to assess whether attention is allocated in space differently when cued by highly motivational stimuli, and if this interplay is further modulated by the vestibular system. In order to evaluate both motivational and attentional assets, we administered a Posner-like cueing task to 30 healthy subjects concurrently receiving sham or galvanic vestibular stimulation (GVS; Left-Anodal and Right-Anodal configurations). The participants had to discriminate targets appearing in either exogenously cued or uncued locations (50% validity); cues predicted the amount of points (0, 2, or 10) and thus money that they could earn for a correct response. The results highlight a robust inhibition of return (IOR) (faster responses for invalidly-cued targets) which was not modulated by different levels of reward or GVS. Across all stimulation sessions, rewards exerted a powerful beneficial effect over performance: reaction times were faster when rewards were at stake. However, this effect was largest in sham, but greatly reduced in GVS conditions, most notably with the Right-Anodal configuration. This is the first evidence for a decreased sensitivity to rewards causally induced by a perturbation of the vestibular system. While future studies will shed light on its neural underpinnings and clinical implications, here we argue that GVS could be a safe and promising way to enrich our understanding of reward processes and eventually tackle the management of patients with aberrant sensitivity to rewards.
Collapse
Affiliation(s)
- Elvio Blini
- Integrative Multisensory Perception Action & Cognition Team (ImpAct), INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center (CRNL), Lyon, France; University of Lyon 1, Lyon, France.
| | - Caroline Tilikete
- Integrative Multisensory Perception Action & Cognition Team (ImpAct), INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center (CRNL), Lyon, France; University of Lyon 1, Lyon, France; Hospices Civils de Lyon, Neuro-Ophthalmology and Neurocognition, Hôpital Neurologique Pierre Wertheimer, Bron, France
| | - Alessandro Farnè
- Integrative Multisensory Perception Action & Cognition Team (ImpAct), INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center (CRNL), Lyon, France; University of Lyon 1, Lyon, France; Hospices Civils de Lyon, Neuro-Immersion & Mouvement et Handicap, Lyon, France
| | - Fadila Hadj-Bouziane
- Integrative Multisensory Perception Action & Cognition Team (ImpAct), INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center (CRNL), Lyon, France; University of Lyon 1, Lyon, France.
| |
Collapse
|
21
|
Leruez S, Verny C, Bonneau D, Procaccio V, Lenaers G, Amati-Bonneau P, Reynier P, Scherer C, Prundean A, Orssaud C, Zanlonghi X, Rougier MB, Tilikete C, Miléa D. Cyclosporine A does not prevent second-eye involvement in Leber's hereditary optic neuropathy. Orphanet J Rare Dis 2018; 13:33. [PMID: 29454364 PMCID: PMC5816422 DOI: 10.1186/s13023-018-0773-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Accepted: 02/04/2018] [Indexed: 11/10/2022] Open
Abstract
BACKRGROUND Evaluation of the efficacy of oral cyclosporine A as a prophylactic agent in preventing second-eye involvement in Leber's hereditary optic neuropathy (LHON) in a prospective, open-label, non-randomized, multicenter pilot study. Only LHON patients aged 18 years or more, with confirmed primary mitochondrial DNA mutations and strictly unilateral optic neuropathy occurring within 6 months prior to enrolment, were included in the study. All these patients, receiving treatment with oral cyclosporine (Neoral®, Novartis) at 2.5 mg/kg/day, were examined at three-month intervals for a year. The primary endpoint was the best corrected visual acuity in the unaffected eye; the secondary endpoints were the best corrected visual acuity in the first eye affected, the mean visual field defect on automated perimetry, the thickness of the perifoveal retinal ganglion cell inner plexiform layer, and the thickness of the peripapillary retinal nerve fiber layer in both eyes. RESULTS Among the 24 patients referred to our institution with genetically confirmed LHON, between July 2011 and April 2014, only five patients, four males and one female, fulfilled the inclusion criteria. Age at enrolment ranged from 19 to 42 years (mean: 27.2 years; median: 26 years), four patients harbored the m.11778G > A pathogenic variant, and one the m.14484 T > C pathogenic variant. The time-interval between the onset of symptoms and inclusion in the study ranged from 7 to 17 weeks (mean: 11.8 weeks; median: 9 weeks). Despite treatment with oral cyclosporine A, all patients eventually experienced bilateral eye involvement, occurring within 11-65 weeks after the initiation of treatment. Over the study time period, the average best corrected visual acuity worsened in the first eye affected; by the end of the study, both eyes were equally affected. CONCLUSIONS Oral cyclosporine, at 2.5 mg/kg/day, did not prevent second-eye involvement in patients with strictly unilateral Leber's hereditary optic neuropathy. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02176733 . Registrated June 25, 2014.
Collapse
Affiliation(s)
- Stéphanie Leruez
- Service d'Ophtalmologie, CHU Angers, 49000, Angers, France.,Institut MITOVASC, UMR CNRS 6015-INSERM1083, Université d'Angers, 49000, Angers, France
| | - Christophe Verny
- Institut MITOVASC, UMR CNRS 6015-INSERM1083, Université d'Angers, 49000, Angers, France.,Centre de référence des maladies neurogénétiques, Service de Neurologie, CHU Angers, 49000, Angers, France
| | - Dominique Bonneau
- Institut MITOVASC, UMR CNRS 6015-INSERM1083, Université d'Angers, 49000, Angers, France
| | - Vincent Procaccio
- Institut MITOVASC, UMR CNRS 6015-INSERM1083, Université d'Angers, 49000, Angers, France
| | - Guy Lenaers
- Institut MITOVASC, UMR CNRS 6015-INSERM1083, Université d'Angers, 49000, Angers, France
| | | | - Pascal Reynier
- Institut MITOVASC, UMR CNRS 6015-INSERM1083, Université d'Angers, 49000, Angers, France
| | - Clarisse Scherer
- Institut MITOVASC, UMR CNRS 6015-INSERM1083, Université d'Angers, 49000, Angers, France.,Centre de référence des maladies neurogénétiques, Service de Neurologie, CHU Angers, 49000, Angers, France
| | - Adriana Prundean
- Institut MITOVASC, UMR CNRS 6015-INSERM1083, Université d'Angers, 49000, Angers, France.,Centre de référence des maladies neurogénétiques, Service de Neurologie, CHU Angers, 49000, Angers, France
| | - Christophe Orssaud
- Unité Fonctionnelle d'Ophtalmologie, Centre de référence des Maladies Rares en Ophtalmologie OPHTARA, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, 75015, Paris, France
| | - Xavier Zanlonghi
- Centre de compétence maladie rare, Clinique Jules Verne, 44300, Nantes, France
| | | | - Caroline Tilikete
- Unité de Neuro-Ophtalmologie, Hospices Civils de Lyon, Hôpital Neurologique, 69677, Bron, France
| | - Dan Miléa
- Service d'Ophtalmologie, CHU Angers, 49000, Angers, France. .,Singapore Eye Research Institute, Singapore National Eye Centre and Duke-NUS, Singapore, Singapore. .,Angers University Hospital, Angers, France.
| |
Collapse
|
22
|
Campbell BCV, van Zwam WH, Goyal M, Menon BK, Dippel DWJ, Demchuk AM, Bracard S, White P, Dávalos A, Majoie CBLM, van der Lugt A, Ford GA, de la Ossa NP, Kelly M, Bourcier R, Donnan GA, Roos YBWEM, Bang OY, Nogueira RG, Devlin TG, van den Berg LA, Clarençon F, Burns P, Carpenter J, Berkhemer OA, Yavagal DR, Pereira VM, Ducrocq X, Dixit A, Quesada H, Epstein J, Davis SM, Jansen O, Rubiera M, Urra X, Micard E, Lingsma HF, Naggara O, Brown S, Guillemin F, Muir KW, van Oostenbrugge RJ, Saver JL, Jovin TG, Hill MD, Mitchell PJ, Berkhemer OA, Fransen PSS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJH, van Walderveen MAA, Staals J, Hofmeijer J, van Oostayen JA, Lycklama à Nijeholt GJ, Boiten J, Brouwer PA, Emmer BJ, de Bruijn SF, van Dijk LC, Kappelle J, Lo RH, van Dijk EJ, de Vries J, de Kort PL, van Rooij WJJ, van den Berg JS, van Hasselt BA, Aerden LA, Dallinga RJ, Visser MC, Bot JC, Vroomen PC, Eshghi O, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gerrits DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach Z, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, van den Berg R, Koudstaal PJ, van Zwam WH, Roos YB, van der Lugt A, van Oostenbrugge RJ, Wakhloo A, Moonis M, Henninger N, Goddeau R, Massari F, Minaeian A, Lozano JD, Ramzan M, Stout C, Patel A, Majoie CB, Tunguturi A, Onteddu S, Carandang R, Howk M, Ribó M, Sanjuan E, Rubiera M, Pagola J, Flores A, Muchada M, Dippel DW, Meler P, Huerga E, Gelabert S, Coscojuela P, Tomasello A, Rodriguez D, Santamarina E, Maisterra O, Boned S, Seró L, Brown MM, Rovira A, Molina CA, Millán M, Muñoz L, Pérez de la Ossa N, Gomis M, Dorado L, López-Cancio E, Palomeras E, Munuera J, Liebig T, García Bermejo P, Remollo S, Castaño C, García-Sort R, Cuadras P, Puyalto P, Hernández-Pérez M, Jiménez M, Martínez-Piñeiro A, Lucente G, Stijnen T, Dávalos A, Chamorro A, Urra X, Obach V, Cervera A, Amaro S, Llull L, Codas J, Balasa M, Navarro J, Andersson T, Ariño H, Aceituno A, Rudilosso S, Renu A, Macho JM, San Roman L, Blasco J, López A, Macías N, Cardona P, Mattle H, Quesada H, Rubio F, Cano L, Lara B, de Miquel MA, Aja L, Serena J, Cobo E, Albers GW, Lees KR, Wahlgren N, Arenillas J, Roberts R, Minhas P, Al-Ajlan F, Salluzzi M, Zimmel L, Patel S, Eesa M, Martí-Fàbregas J, Jankowitz B, van der Heijden E, Serena J, Salvat-Plana M, López-Cancio E, Bracard S, Ducrocq X, Anxionnat R, Baillot PA, Barbier C, Derelle AL, Lacour JC, Ghannouti N, Richard S, Samson Y, Sourour N, Baronnet-Chauvet F, Clarencon F, Crozier S, Deltour S, Di Maria F, Le Bouc R, Leger A, Fleitour N, Mutlu G, Rosso C, Szatmary Z, Yger M, Zavanone C, Bakchine S, Pierot L, Caucheteux N, Estrade L, Kadziolka K, Hooijenga I, Leautaud A, Renkes C, Serre I, Desal H, Guillon B, Boutoleau-Bretonniere C, Daumas-Duport B, De Gaalon S, Derkinderen P, Evain S, Puppels C, Herisson F, Laplaud DA, Lebouvier T, Lintia-Gaultier A, Pouclet-Courtemanche H, Rouaud T, Rouaud Jaffrenou V, Schunck A, Sevin-Allouet M, Toulgoat F, Pellikaan W, Wiertlewski S, Gauvrit JY, Ronziere T, Cahagne V, Ferre JC, Pinel JF, Raoult H, Mas JL, Meder JF, Al Najjar-Carpentier AA, Geerling A, Birchenall J, Bodiguel E, Calvet D, Domigo V, Godon-Hardy S, Guiraud V, Lamy C, Majhadi L, Morin L, Naggara O, Lindl-Velema A, Trystram D, Turc G, Berge J, Sibon I, Menegon P, Barreau X, Rouanet F, Debruxelles S, Kazadi A, Renou P, van Vemde G, Fleury O, Pasco-Papon A, Dubas F, Caroff J, Godard Ducceschi S, Hamon MA, Lecluse A, Marc G, Giroud M, Ricolfi F, de Ridder A, Bejot Y, Chavent A, Gentil A, Kazemi A, Osseby GV, Voguet C, Mahagne MH, Sedat J, Chau Y, Suissa L, Greebe P, Lachaud S, Houdart E, Stapf C, Buffon Porcher F, Chabriat H, Guedin P, Herve D, Jouvent E, Mawet J, Saint-Maurice JP, de Bont-Stikkelbroeck J, Schneble HM, Turjman F, Nighoghossian N, Berhoune NN, Bouhour F, Cho TH, Derex L, Felix S, Gervais-Bernard H, Gory B, de Meris J, Manera L, Mechtouff L, Ritzenthaler T, Riva R, Salaris Silvio F, Tilikete C, Blanc R, Obadia M, Bartolini MB, Gueguen A, Janssen K, Piotin M, Pistocchi S, Redjem H, Drouineau J, Neau JP, Godeneche G, Lamy M, Marsac E, Velasco S, Clavelou P, Struijk W, Chabert E, Bourgois N, Cornut-Chauvinc C, Ferrier A, Gabrillargues J, Jean B, Marques AR, Vitello N, Detante O, Barbieux M, Licher S, Boubagra K, Favre Wiki I, Garambois K, Tahon F, Ashok V, Voguet C, Coskun O, Guedin P, Rodesch G, Lapergue B, Boodt N, Bourdain F, Evrard S, Graveleau P, Decroix JP, Wang A, Sellal F, Ahle G, Carelli G, Dugay MH, Gaultier C, Ros A, Lebedinsky AP, Lita L, Musacchio RM, Renglewicz-Destuynder C, Tournade A, Vuillemet F, Montoro FM, Mounayer C, Faugeras F, Gimenez L, Venema E, Labach C, Lautrette G, Denier C, Saliou G, Chassin O, Dussaule C, Melki E, Ozanne A, Puccinelli F, Sachet M, Slokkers I, Sarov M, Bonneville JF, Moulin T, Biondi A, De Bustos Medeiros E, Vuillier F, Courtheoux P, Viader F, Apoil-Brissard M, Bataille M, Ganpat RJ, Bonnet AL, Cogez J, Kazemi A, Touze E, Leclerc X, Leys D, Aggour M, Aguettaz P, Bodenant M, Cordonnier C, Mulder M, Deplanque D, Girot M, Henon H, Kalsoum E, Lucas C, Pruvo JP, Zuniga P, Bonafé A, Arquizan C, Costalat V, Saiedie N, Machi P, Mourand I, Riquelme C, Bounolleau P, Arteaga C, Faivre A, Bintner M, Tournebize P, Charlin C, Darcel F, Heshmatollah A, Gauthier-Lasalarie P, Jeremenko M, Mouton S, Zerlauth JB, Lamy C, Hervé D, Hassan H, Gaston A, Barral FG, Garnier P, Schipperen S, Beaujeux R, Wolff V, Herbreteau D, Debiais S, Murray A, Ford G, Muir KW, White P, Brown MM, Clifton A, Vinken S, Freeman J, Ford I, Markus H, Wardlaw J, Lees KR, Molyneux A, Robinson T, Lewis S, Norrie J, Robertson F, van Boxtel T, Perry R, Dixit A, Cloud G, Clifton A, Madigan J, Roffe C, Nayak S, Lobotesis K, Smith C, Herwadkar A, Koets J, Kandasamy N, Goddard T, Bamford J, Subramanian G, Lenthall R, Littleton E, Lamin S, Storey K, Ghatala R, Banaras A, Boers M, Aeron-Thomas J, Hazel B, Maguire H, Veraque E, Harrison L, Keshvara R, Cunningham J, Santos E, Borst J, Jansen I, Kappelhof M, Lucas M, Geuskens R, Barros RS, Dobbe R, Csizmadia M, Hill MD, Goyal M, Demchuk AM, Menon BK, Eesa M, Ryckborst KJ, Wright MR, Kamal NR, Andersen L, Randhawa PA, Stewart T, Patil S, Minhas P, Almekhlafi M, Mishra S, Clement F, Sajobi T, Shuaib A, Montanera WJ, Roy D, Silver FL, Jovin TG, Frei DF, Sapkota B, Rempel JL, Thornton J, Williams D, Tampieri D, Poppe AY, Dowlatshahi D, Wong JH, Mitha AP, Subramaniam S, Hull G, Lowerison MW, Sajobi T, Salluzzi M, Wright MR, Maxwell M, Lacusta S, Drupals E, Armitage K, Barber PA, Smith EE, Morrish WF, Coutts SB, Derdeyn C, Demaerschalk B, Yavagal D, Martin R, Brant R, Yu Y, Willinsky RA, Montanera WJ, Weill A, Kenney C, Aram H, Stewart T, Stys PK, Watson TW, Klein G, Pearson D, Couillard P, Trivedi A, Singh D, Klourfeld E, Imoukhuede O, Nikneshan D, Blayney S, Reddy R, Choi P, Horton M, Musuka T, Dubuc V, Field TS, Desai J, Adatia S, Alseraya A, Nambiar V, van Dijk R, Wong JH, Mitha AP, Morrish WF, Eesa M, Newcommon NJ, Shuaib A, Schwindt B, Butcher KS, Jeerakathil T, Buck B, Khan K, Naik SS, Emery DJ, Owen RJ, Kotylak TB, Ashforth RA, Yeo TA, McNally D, Siddiqui M, Saqqur M, Hussain D, Kalashyan H, Manosalva A, Kate M, Gioia L, Hasan S, Mohammad A, Muratoglu M, Williams D, Thornton J, Cullen A, Brennan P, O'Hare A, Looby S, Hyland D, Duff S, McCusker M, Hallinan B, Lee S, McCormack J, Moore A, O'Connor M, Donegan C, Brewer L, Martin A, Murphy S, O'Rourke K, Smyth S, Kelly P, Lynch T, Daly T, O'Brien P, O'Driscoll A, Martin M, Daly T, Collins R, Coughlan T, McCabe D, Murphy S, O'Neill D, Mulroy M, Lynch O, Walsh T, O'Donnell M, Galvin T, Harbison J, McElwaine P, Mulpeter K, McLoughlin C, Reardon M, Harkin E, Dolan E, Watts M, Cunningham N, Fallon C, Gallagher S, Cotter P, Crowe M, Doyle R, Noone I, Lapierre M, Coté VA, Lanthier S, Odier C, Durocher A, Raymond J, Weill A, Daneault N, Deschaintre Y, Jankowitz B, Baxendell L, Massaro L, Jackson-Graves C, Decesare S, Porter P, Armbruster K, Adams A, Billigan J, Oakley J, Ducruet A, Jadhav A, Giurgiutiu DV, Aghaebrahim A, Reddy V, Hammer M, Starr M, Totoraitis V, Wechsler L, Streib S, Rangaraju S, Campbell D, Rocha M, Gulati D, Silver FL, Krings T, Kalman L, Cayley A, Williams J, Stewart T, Wiegner R, Casaubon LK, Jaigobin C, del Campo JM, Elamin E, Schaafsma JD, Willinsky RA, Agid R, Farb R, ter Brugge K, Sapkoda BL, Baxter BW, Barton K, Knox A, Porter A, Sirelkhatim A, Devlin T, Dellinger C, Pitiyanuvath N, Patterson J, Nichols J, Quarfordt S, Calvert J, Hawk H, Fanale C, Frei DF, Bitner A, Novak A, Huddle D, Bellon R, Loy D, Wagner J, Chang I, Lampe E, Spencer B, Pratt R, Bartt R, Shine S, Dooley G, Nguyen T, Whaley M, McCarthy K, Teitelbaum J, Tampieri D, Poon W, Campbell N, Cortes M, Dowlatshahi D, Lum C, Shamloul R, Robert S, Stotts G, Shamy M, Steffenhagen N, Blacquiere D, Hogan M, AlHazzaa M, Basir G, Lesiuk H, Iancu D, Santos M, Choe H, Weisman DC, Jonczak K, Blue-Schaller A, Shah Q, MacKenzie L, Klein B, Kulandaivel K, Kozak O, Gzesh DJ, Harris LJ, Khoury JS, Mandzia J, Pelz D, Crann S, Fleming L, Hesser K, Beauchamp B, Amato-Marzialli B, Boulton M, Lopez- Ojeda P, Sharma M, Lownie S, Chan R, Swartz R, Howard P, Golob D, Gladstone D, Boyle K, Boulos M, Hopyan J, Yang V, Da Costa L, Holmstedt CA, Turk AS, Navarro R, Jauch E, Ozark S, Turner R, Phillips S, Shankar J, Jarrett J, Gubitz G, Maloney W, Vandorpe R, Schmidt M, Heidenreich J, Hunter G, Kelly M, Whelan R, Peeling L, Burns PA, Hunter A, Wiggam I, Kerr E, Watt M, Fulton A, Gordon P, Rennie I, Flynn P, Smyth G, O'Leary S, Gentile N, Linares G, McNelis P, Erkmen K, Katz P, Azizi A, Weaver M, Jungreis C, Faro S, Shah P, Reimer H, Kalugdan V, Saposnik G, Bharatha A, Li Y, Kostyrko P, Santos M, Marotta T, Montanera W, Sarma D, Selchen D, Spears J, Heo JH, Jeong K, Kim DJ, Kim BM, Kim YD, Song D, Lee KJ, Yoo J, Bang OY, Rho S, Lee J, Jeon P, Kim KH, Cha J, Kim SJ, Ryoo S, Lee MJ, Sohn SI, Kim CH, Ryu HG, Hong JH, Chang HW, Lee CY, Rha J, Davis SM, Donnan GA, Campbell BCV, Mitchell PJ, Churilov L, Yan B, Dowling R, Yassi N, Oxley TJ, Wu TY, Silver G, McDonald A, McCoy R, Kleinig TJ, Scroop R, Dewey HM, Simpson M, Brooks M, Coulton B, Krause M, Harrington TJ, Steinfort B, Faulder K, Priglinger M, Day S, Phan T, Chong W, Holt M, Chandra RV, Ma H, Young D, Wong K, Wijeratne T, Tu H, Mackay E, Celestino S, Bladin CF, Loh PS, Gilligan A, Ross Z, Coote S, Frost T, Parsons MW, Miteff F, Levi CR, Ang T, Spratt N, Kaauwai L, Badve M, Rice H, de Villiers L, Barber PA, McGuinness B, Hope A, Moriarty M, Bennett P, Wong A, Coulthard A, Lee A, Jannes J, Field D, Sharma G, Salinas S, Cowley E, Snow B, Kolbe J, Stark R, King J, Macdonnell R, Attia J, D'Este C, Saver JL, Goyal M, Diener HC, Levy EI, Bonafé A, Mendes Pereira V, Jahan R, Albers GW, Cognard C, Cohen DJ, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, von Kummer R, Smith W, Turjman F, Hamilton S, Chiacchierini R, Amar A, Sanossian N, Loh Y, Devlin T, Baxter B, Hawk H, Sapkota B, Quarfordt S, Sirelkhatim A, Dellinger C, Barton K, Reddy VK, Ducruet A, Jadhav A, Horev A, Giurgiutiu DV, Totoraitis V, Hammer M, Jankowitz B, Wechsler L, Rocha M, Gulati D, Campbell D, Star M, Baxendell L, Oakley J, Siddiqui A, Hopkins LN, Snyder K, Sawyer R, Hall S, Costalat V, Riquelme C, Machi P, Omer E, Arquizan C, Mourand I, Charif M, Ayrignac X, Menjot de Champfleur N, Leboucq N, Gascou G, Moynier M, du Mesnil de Rochemont R, Singer O, Berkefeld J, Foerch C, Lorenz M, Pfeilschifer W, Hattingen E, Wagner M, You SJ, Lescher S, Braun H, Dehkharghani S, Belagaje SR, Anderson A, Lima A, Obideen M, Haussen D, Dharia R, Frankel M, Patel V, Owada K, Saad A, Amerson L, Horn C, Doppelheuer S, Schindler K, Lopes DK, Chen M, Moftakhar R, Anton C, Smreczak M, Carpenter JS, Boo S, Rai A, Roberts T, Tarabishy A, Gutmann L, Brooks C, Brick J, Domico J, Reimann G, Hinrichs K, Becker M, Heiss E, Selle C, Witteler A, Al-Boutros S, Danch MJ, Ranft A, Rohde S, Burg K, Weimar C, Zegarac V, Hartmann C, Schlamann M, Göricke S, Ringlestein A, Wanke I, Mönninghoff C, Dietzold M, Budzik R, Davis T, Eubank G, Hicks WJ, Pema P, Vora N, Mejilla J, Taylor M, Clark W, Rontal A, Fields J, Peterson B, Nesbit G, Lutsep H, Bozorgchami H, Priest R, Ologuntoye O, Barnwell S, Dogan A, Herrick K, Takahasi C, Beadell N, Brown B, Jamieson S, Hussain MS, Russman A, Hui F, Wisco D, Uchino K, Khawaja Z, Katzan I, Toth G, Cheng-Ching E, Bain M, Man S, Farrag A, George P, John S, Shankar L, Drofa A, Dahlgren R, Bauer A, Itreat A, Taqui A, Cerejo R, Richmond A, Ringleb P, Bendszus M, Möhlenbruch M, Reiff T, Amiri H, Purrucker J, Herweh C, Pham M, Menn O, Ludwig I, Acosta I, Villar C, Morgan W, Sombutmai C, Hellinger F, Allen E, Bellew M, Gandhi R, Bonwit E, Aly J, Ecker RD, Seder D, Morris J, Skaletsky M, Belden J, Baker C, Connolly LS, Papanagiotou P, Roth C, Kastrup A, Politi M, Brunner F, Alexandrou M, Merdivan H, Ramsey C, Given II C, Renfrow S, Deshmukh V, Sasadeusz K, Vincent F, Thiesing JT, Putnam J, Bhatt A, Kansara A, Caceves D, Lowenkopf T, Yanase L, Zurasky J, Dancer S, Freeman B, Scheibe-Mirek T, Robison J, Rontal A, Roll J, Clark D, Rodriguez M, Fitzsimmons BFM, Zaidat O, Lynch JR, Lazzaro M, Larson T, Padmore L, Das E, Farrow-Schmidt A, Hassan A, Tekle W, Cate C, Jansen O, Cnyrim C, Wodarg F, Wiese C, Binder A, Riedel C, Rohr A, Lang N, Laufs H, Krieter S, Remonda L, Diepers M, Añon J, Nedeltchev K, Kahles T, Biethahn S, Lindner M, Chang V, Gächter C, Esperon C, Guglielmetti M, Arenillas Lara JF, Martínez Galdámez M, Calleja Sanz AI, Cortijo Garcia E, Garcia Bermejo P, Perez S, Mulero Carrillo P, Crespo Vallejo E, Ruiz Piñero M, Lopez Mesonero L, Reyes Muñoz FJ, Brekenfeld C, Buhk JH, Krützelmann A, Thomalla G, Cheng B, Beck C, Hoppe J, Goebell E, Holst B, Grzyska U, Wortmann G, Starkman S, Duckwiler G, Jahan R, Rao N, Sheth S, Ng K, Noorian A, Szeder V, Nour M, McManus M, Huang J, Tarpley J, Tateshima S, Gonzalez N, Ali L, Liebeskind D, Hinman J, Calderon-Arnulphi M, Liang C, Guzy J, Koch S, DeSousa K, Gordon-Perue G, Haussen D, Elhammady M, Peterson E, Pandey V, Dharmadhikari S, Khandelwal P, Malik A, Pafford R, Gonzalez P, Ramdas K, Andersen G, Damgaard D, Von Weitzel-Mudersbach P, Simonsen C, Ruiz de Morales Ayudarte N, Poulsen M, Sørensen L, Karabegovich S, Hjørringgaard M, Hjort N, Harbo T, Sørensen K, Deshaies E, Padalino D, Swarnkar A, Latorre JG, Elnour E, El-Zammar Z, Villwock M, Farid H, Balgude A, Cross L, Hansen K, Holtmannspötter M, Kondziella D, Hoejgaard J, Taudorf S, Soendergaard H, Wagner A, Cronquist M, Stavngaard T, Cortsen M, Krarup LH, Hyldal T, Haring HP, Guggenberger S, Hamberger M, Trenkler J, Sonnberger M, Nussbaumer K, Dominger C, Bach E, Jagadeesan BD, Taylor R, Kim J, Shea K, Tummala R, Zacharatos H, Sandhu D, Ezzeddine M, Grande A, Hildebrandt D, Miller K, Scherber J, Hendrickson A, Jumaa M, Zaidi S, Hendrickson T, Snyder V, Killer-Oberpfalzer M, Mutzenbach J, Weymayr F, Broussalis E, Stadler K, Jedlitschka A, Malek A, Mueller-Kronast N, Beck P, Martin C, Summers D, Day J, Bettinger I, Holloway W, Olds K, Arkin S, Akhtar N, Boutwell C, Crandall S, Schwartzman M, Weinstein C, Brion B, Prothmann S, Kleine J, Kreiser K, Boeckh-Behrens T, Poppert H, Wunderlich S, Koch ML, Biberacher V, Huberle A, Gora-Stahlberg G, Knier B, Meindl T, Utpadel-Fischler D, Zech M, Kowarik M, Seifert C, Schwaiger B, Puri A, Hou S. Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data. Lancet Neurol 2018; 17:47-53. [DOI: 10.1016/s1474-4422(17)30407-6] [Citation(s) in RCA: 129] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 10/05/2017] [Accepted: 10/11/2017] [Indexed: 10/18/2022]
|
23
|
Ibáñez-Juliá MJ, Pappa E, Gaymard B, Leclercq D, Hautefort C, Tilikete C, Delattre JY, Hoang-Xuan K, Psimaras D, Alentorn A. Brain volumetric analysis and cortical thickness in adults with saccadic intrusions (ocular flutter or opsoclonus-myoclonus syndrome). Clin Neurol Neurosurg 2017; 163:167-172. [PMID: 29121544 DOI: 10.1016/j.clineuro.2017.10.028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Revised: 09/24/2017] [Accepted: 10/28/2017] [Indexed: 11/17/2022]
Abstract
OBJECTIVES Ocular flutter (OF) and opsoclonus are considered a continuum with a similar pathogenesis. Due to the rarity of this disease in the adult population, little is known about the brain morphological changes in the chronic phase of the disease. PATIENTS AND METHODS Six magnetic resonance imaging from adults with previous history of OF/Opsoclonus and 12 healthy patients (paired by age and sex) were analyzed in order to identify the long term cortical thickness pattern in this rare disease by using Freesurfer. RESULTS Patients with OF/Opsoclonus showed reduced cerebellum cortical volume with a subsequent diminution in total cerebellar volume. White mater cerebellum volume was not modified. In addition, we have also identified a significant supratentorial gray matter volume decrease in OF/Opsoclonus patients, involving both the cortical and the subcortical gray matter. CONCLUSIONS OF/Opsoclonus in adults may be associated with cortical and subcortical gray matter atrophy, as well as decreased cerebellar cortical volume. Further larger prospective studies are necessary to confirm these results.
Collapse
Affiliation(s)
- María-José Ibáñez-Juliá
- Department of Neurology 2, Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), 75013, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris VI, 75013, Paris, France; Institut du Cerveau et de la Moelle Epinière, INSERM U1127 and Centre National de la Recherche Scientifique, Unité de Recherche Mixte, 7225, Paris, France
| | - Evangelia Pappa
- Department of Neurology 2, Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), 75013, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris VI, 75013, Paris, France; Institut du Cerveau et de la Moelle Epinière, INSERM U1127 and Centre National de la Recherche Scientifique, Unité de Recherche Mixte, 7225, Paris, France
| | - Bertrand Gaymard
- Deparment of Clinical Neurophysiology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), 75013, Paris, France
| | - Delphine Leclercq
- Department of Neuro-radiology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), 75013, Paris, France
| | - Charlotte Hautefort
- Otolaryngology - Head and Neck Surgery Department, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris (AP-HP), 75475, Paris, France
| | - Caroline Tilikete
- Neuro-Ophthalmology Unit, Lyon Civil Hospitals, Neurological Hospital, Lyon 1 University, Bron Cedex, France
| | - Jean-Yves Delattre
- Department of Neurology 2, Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), 75013, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris VI, 75013, Paris, France; Institut du Cerveau et de la Moelle Epinière, INSERM U1127 and Centre National de la Recherche Scientifique, Unité de Recherche Mixte, 7225, Paris, France
| | - Khê Hoang-Xuan
- Department of Neurology 2, Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), 75013, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris VI, 75013, Paris, France; Institut du Cerveau et de la Moelle Epinière, INSERM U1127 and Centre National de la Recherche Scientifique, Unité de Recherche Mixte, 7225, Paris, France
| | - Dimitri Psimaras
- Department of Neurology 2, Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), 75013, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris VI, 75013, Paris, France; Institut du Cerveau et de la Moelle Epinière, INSERM U1127 and Centre National de la Recherche Scientifique, Unité de Recherche Mixte, 7225, Paris, France
| | - Agusti Alentorn
- Department of Neurology 2, Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), 75013, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Université Paris VI, 75013, Paris, France; Institut du Cerveau et de la Moelle Epinière, INSERM U1127 and Centre National de la Recherche Scientifique, Unité de Recherche Mixte, 7225, Paris, France.
| |
Collapse
|
24
|
Abstract
Hypertrophic degeneration of the inferior olive is mainly observed in patients developing palatal tremor (PT) or oculopalatal tremor (OPT). This syndrome manifests as a synchronous tremor of the palate (PT) and/or eyes (OPT) that may also involve other muscles from the branchial arches. It is associated with hypertrophic inferior olivary degeneration that is characterized by enlarged and vacuolated neurons, increased number and size of astrocytes, severe fibrillary gliosis, and demyelination. It appears on MRI as an increased T2/FLAIR signal intensity and enlargement of the inferior olive. There are two main conditions in which hypertrophic degeneration of the inferior olive occurs. The most frequent, studied, and reported condition is the development of PT/OPT and hypertrophic degeneration of the inferior olive in the weeks or months following a structural brainstem or cerebellar lesion. This “symptomatic” condition requires a destructive lesion in the Guillain–Mollaret pathway, which spans from the contralateral dentate nucleus via the brachium conjunctivum and the ipsilateral central tegmental tract innervating the inferior olive. The most frequent etiologies of destructive lesion are stroke (hemorrhagic more often than ischemic), brain trauma, brainstem tumors, and surgical or gamma knife treatment of brainstem cavernoma. The most accepted explanation for this symptomatic PT/OPT is that denervated olivary neurons released from inhibitory inputs enlarge and develop sustained synchronized oscillations. The cerebellum then modulates/accentuates this signal resulting in abnormal motor output in the branchial arches. In a second condition, PT/OPT and progressive cerebellar ataxia occurs in patients without structural brainstem or cerebellar lesion, other than cerebellar atrophy. This syndrome of progressive ataxia and palatal tremor may be sporadic or familial. In the familial form, where hypertrophic degeneration of the inferior olive may not occur (or not reported), the main reported etiologies are Alexander disease, polymerase gamma mutation, and spinocerebellar ataxia type 20. Whether or not these are associated with specific degeneration of the dentato–olivary pathway remain to be determined. The most symptomatic consequence of OPT is eye oscillations. Therapeutic trials suggest gabapentin or memantine as valuable drugs to treat eye oscillations in OPT.
Collapse
Affiliation(s)
- Caroline Tilikete
- Neuro-Ophthalmology and Neurocognition, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.,Lyon I University, Lyon, France.,ImpAct Team, CRNL INSERM U1028 CNRS UMR5292, Bron, France
| | - Virginie Desestret
- Neuro-Ophthalmology and Neurocognition, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.,Lyon I University, Lyon, France.,SynatAc Team, Institut NeuroMyogène INSERM U1217/UMR CRS 5310, Lyon, France
| |
Collapse
|
25
|
Biotti D, Tilikete C. Teaching Video Neuro
Images
: Bilateral complete horizontal gaze palsy with preserved convergence. Neurology 2016; 87:e117-8. [DOI: 10.1212/wnl.0000000000003096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
26
|
Lebranchu P, Berthoz A, Kahane P, Lachaux JP, Tilikete C, Orban GA, Bastin J. Influence of the referential framework in the human pursuit coding system. Neurology 2016; 87:1517-1518. [PMID: 27590292 DOI: 10.1212/wnl.0000000000003172] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Accepted: 06/17/2016] [Indexed: 11/15/2022] Open
Affiliation(s)
- Pierre Lebranchu
- From the UMR 7152 (P.L., A.B., J.B.), CNRS-Collège de France, Laboratoire de Physiologie de la Perception et de l'Action, Paris; Clinique Ophtalmologique (P.L.), CHU Hôtel Dieu (P.K., J.B.), Nantes; Université Grenoble Alpes, Grenoble; INSERM U836 (P.K., J.B.), Grenoble Institut des Neurosciences, Grenoble; Neurology Department (P.K.), Michallon Hospital, Grenoble; Lyon Neuroscience Research Center (J.-P.L.), Brain Dynamics and Cognition Team, CRNL, INSERM U1028, CNRS UMR5292, Lyon; University Lyon 1 (J.-P.L.), Lyon; Hospices Civils de Lyon (C.T.), Neuro-ophthalmology Unit and Neurology D, Hôpital P Wertheimer, Lyon; INSERM U1028 (C.T.), CNRS UMR5292, IMPACT Team, Lyon Neuroscience Research Center, Lyon, France; Laboratorium voor Neuro-en Psychofysiologie (G.A.O.), K.U. Leuven Medical School, Leuven, Belgium; and Department of Neuroscience (G.A.O.), University of Parma, Italy.
| | - Alain Berthoz
- From the UMR 7152 (P.L., A.B., J.B.), CNRS-Collège de France, Laboratoire de Physiologie de la Perception et de l'Action, Paris; Clinique Ophtalmologique (P.L.), CHU Hôtel Dieu (P.K., J.B.), Nantes; Université Grenoble Alpes, Grenoble; INSERM U836 (P.K., J.B.), Grenoble Institut des Neurosciences, Grenoble; Neurology Department (P.K.), Michallon Hospital, Grenoble; Lyon Neuroscience Research Center (J.-P.L.), Brain Dynamics and Cognition Team, CRNL, INSERM U1028, CNRS UMR5292, Lyon; University Lyon 1 (J.-P.L.), Lyon; Hospices Civils de Lyon (C.T.), Neuro-ophthalmology Unit and Neurology D, Hôpital P Wertheimer, Lyon; INSERM U1028 (C.T.), CNRS UMR5292, IMPACT Team, Lyon Neuroscience Research Center, Lyon, France; Laboratorium voor Neuro-en Psychofysiologie (G.A.O.), K.U. Leuven Medical School, Leuven, Belgium; and Department of Neuroscience (G.A.O.), University of Parma, Italy
| | - Philippe Kahane
- From the UMR 7152 (P.L., A.B., J.B.), CNRS-Collège de France, Laboratoire de Physiologie de la Perception et de l'Action, Paris; Clinique Ophtalmologique (P.L.), CHU Hôtel Dieu (P.K., J.B.), Nantes; Université Grenoble Alpes, Grenoble; INSERM U836 (P.K., J.B.), Grenoble Institut des Neurosciences, Grenoble; Neurology Department (P.K.), Michallon Hospital, Grenoble; Lyon Neuroscience Research Center (J.-P.L.), Brain Dynamics and Cognition Team, CRNL, INSERM U1028, CNRS UMR5292, Lyon; University Lyon 1 (J.-P.L.), Lyon; Hospices Civils de Lyon (C.T.), Neuro-ophthalmology Unit and Neurology D, Hôpital P Wertheimer, Lyon; INSERM U1028 (C.T.), CNRS UMR5292, IMPACT Team, Lyon Neuroscience Research Center, Lyon, France; Laboratorium voor Neuro-en Psychofysiologie (G.A.O.), K.U. Leuven Medical School, Leuven, Belgium; and Department of Neuroscience (G.A.O.), University of Parma, Italy
| | - Jean-Philippe Lachaux
- From the UMR 7152 (P.L., A.B., J.B.), CNRS-Collège de France, Laboratoire de Physiologie de la Perception et de l'Action, Paris; Clinique Ophtalmologique (P.L.), CHU Hôtel Dieu (P.K., J.B.), Nantes; Université Grenoble Alpes, Grenoble; INSERM U836 (P.K., J.B.), Grenoble Institut des Neurosciences, Grenoble; Neurology Department (P.K.), Michallon Hospital, Grenoble; Lyon Neuroscience Research Center (J.-P.L.), Brain Dynamics and Cognition Team, CRNL, INSERM U1028, CNRS UMR5292, Lyon; University Lyon 1 (J.-P.L.), Lyon; Hospices Civils de Lyon (C.T.), Neuro-ophthalmology Unit and Neurology D, Hôpital P Wertheimer, Lyon; INSERM U1028 (C.T.), CNRS UMR5292, IMPACT Team, Lyon Neuroscience Research Center, Lyon, France; Laboratorium voor Neuro-en Psychofysiologie (G.A.O.), K.U. Leuven Medical School, Leuven, Belgium; and Department of Neuroscience (G.A.O.), University of Parma, Italy
| | - Caroline Tilikete
- From the UMR 7152 (P.L., A.B., J.B.), CNRS-Collège de France, Laboratoire de Physiologie de la Perception et de l'Action, Paris; Clinique Ophtalmologique (P.L.), CHU Hôtel Dieu (P.K., J.B.), Nantes; Université Grenoble Alpes, Grenoble; INSERM U836 (P.K., J.B.), Grenoble Institut des Neurosciences, Grenoble; Neurology Department (P.K.), Michallon Hospital, Grenoble; Lyon Neuroscience Research Center (J.-P.L.), Brain Dynamics and Cognition Team, CRNL, INSERM U1028, CNRS UMR5292, Lyon; University Lyon 1 (J.-P.L.), Lyon; Hospices Civils de Lyon (C.T.), Neuro-ophthalmology Unit and Neurology D, Hôpital P Wertheimer, Lyon; INSERM U1028 (C.T.), CNRS UMR5292, IMPACT Team, Lyon Neuroscience Research Center, Lyon, France; Laboratorium voor Neuro-en Psychofysiologie (G.A.O.), K.U. Leuven Medical School, Leuven, Belgium; and Department of Neuroscience (G.A.O.), University of Parma, Italy
| | - Guy A Orban
- From the UMR 7152 (P.L., A.B., J.B.), CNRS-Collège de France, Laboratoire de Physiologie de la Perception et de l'Action, Paris; Clinique Ophtalmologique (P.L.), CHU Hôtel Dieu (P.K., J.B.), Nantes; Université Grenoble Alpes, Grenoble; INSERM U836 (P.K., J.B.), Grenoble Institut des Neurosciences, Grenoble; Neurology Department (P.K.), Michallon Hospital, Grenoble; Lyon Neuroscience Research Center (J.-P.L.), Brain Dynamics and Cognition Team, CRNL, INSERM U1028, CNRS UMR5292, Lyon; University Lyon 1 (J.-P.L.), Lyon; Hospices Civils de Lyon (C.T.), Neuro-ophthalmology Unit and Neurology D, Hôpital P Wertheimer, Lyon; INSERM U1028 (C.T.), CNRS UMR5292, IMPACT Team, Lyon Neuroscience Research Center, Lyon, France; Laboratorium voor Neuro-en Psychofysiologie (G.A.O.), K.U. Leuven Medical School, Leuven, Belgium; and Department of Neuroscience (G.A.O.), University of Parma, Italy
| | - Julien Bastin
- From the UMR 7152 (P.L., A.B., J.B.), CNRS-Collège de France, Laboratoire de Physiologie de la Perception et de l'Action, Paris; Clinique Ophtalmologique (P.L.), CHU Hôtel Dieu (P.K., J.B.), Nantes; Université Grenoble Alpes, Grenoble; INSERM U836 (P.K., J.B.), Grenoble Institut des Neurosciences, Grenoble; Neurology Department (P.K.), Michallon Hospital, Grenoble; Lyon Neuroscience Research Center (J.-P.L.), Brain Dynamics and Cognition Team, CRNL, INSERM U1028, CNRS UMR5292, Lyon; University Lyon 1 (J.-P.L.), Lyon; Hospices Civils de Lyon (C.T.), Neuro-ophthalmology Unit and Neurology D, Hôpital P Wertheimer, Lyon; INSERM U1028 (C.T.), CNRS UMR5292, IMPACT Team, Lyon Neuroscience Research Center, Lyon, France; Laboratorium voor Neuro-en Psychofysiologie (G.A.O.), K.U. Leuven Medical School, Leuven, Belgium; and Department of Neuroscience (G.A.O.), University of Parma, Italy
| |
Collapse
|
27
|
Lévy-Bencheton D, Khan AZ, Pélisson D, Tilikete C, Pisella L. Adaptation of Saccadic Sequences with and without Remapping. Front Hum Neurosci 2016; 10:359. [PMID: 27499735 PMCID: PMC4956671 DOI: 10.3389/fnhum.2016.00359] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2016] [Accepted: 07/01/2016] [Indexed: 11/13/2022] Open
Abstract
It is relatively easy to adapt visually-guided saccades because the visual vector and the saccade vector match. The retinal error at the saccade landing position is compared to the prediction error, based on target location and efference copy. If these errors do not match, planning processes at the level(s) of the visual and/or motor vector processing are assumed to be inaccurate and the saccadic response is adjusted. In the case of a sequence of two saccades, the final error can be attributed to the last saccade vector or to the entire saccadic displacement. Here, we asked whether and how adaptation can occur in the case of remapped saccades, such as during the classic double-step saccade paradigm, where the visual and motor vectors of the second saccade do not coincide and so the attribution of error is ambiguous. Participants performed saccades sequences to two targets briefly presented prior to first saccade onset. The second saccade target was either briefly re-illuminated (sequential visually-guided task) or not (remapping task) upon first saccade offset. To drive adaptation, the second target was presented at a displaced location (backward or forward jump condition or control-no jump) at the end of the second saccade. Pre- and post-adaptation trials were identical, without the re-appearance of the target after the second saccade. For the 1st saccade endpoints, there was no change as a function of adaptation. For the 2nd saccade, there was a similar increase in gain in the forward jump condition (52% and 61% of target jump) in the two tasks, whereas the gain decrease in the backward condition was much smaller for the remapping task than for the sequential visually-guided task (41% vs. 94%). In other words, the absolute gain change was similar between backward and forward adaptation for remapped saccades. In conclusion, we show that remapped saccades can be adapted, suggesting that the error is attributed to the visuo-motor transformation of the remapped visual vector. The mechanisms by which adaptation takes place for remapped saccades may be similar to those of forward sequential visually-guided saccades, unlike those involved in adaptation for backward sequential visually-guided saccades.
Collapse
Affiliation(s)
- Delphine Lévy-Bencheton
- Centre de Recherche en Neurosciences de Lyon (CRNL), ImpAct team, Inserm U1028, CNRS UMR 5292, Lyon1 University Bron, France
| | | | - Denis Pélisson
- Centre de Recherche en Neurosciences de Lyon (CRNL), ImpAct team, Inserm U1028, CNRS UMR 5292, Lyon1 University Bron, France
| | - Caroline Tilikete
- Centre de Recherche en Neurosciences de Lyon (CRNL), ImpAct team, Inserm U1028, CNRS UMR 5292, Lyon1 University Bron, France
| | - Laure Pisella
- Centre de Recherche en Neurosciences de Lyon (CRNL), ImpAct team, Inserm U1028, CNRS UMR 5292, Lyon1 University Bron, France
| |
Collapse
|
28
|
Bodranghien F, Bastian A, Casali C, Hallett M, Louis ED, Manto M, Mariën P, Nowak DA, Schmahmann JD, Serrao M, Steiner KM, Strupp M, Tilikete C, Timmann D, van Dun K. Consensus Paper: Revisiting the Symptoms and Signs of Cerebellar Syndrome. Cerebellum 2016; 15:369-91. [PMID: 26105056 PMCID: PMC5565264 DOI: 10.1007/s12311-015-0687-3] [Citation(s) in RCA: 206] [Impact Index Per Article: 25.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The cerebellum is involved in sensorimotor operations, cognitive tasks and affective processes. Here, we revisit the concept of the cerebellar syndrome in the light of recent advances in our understanding of cerebellar operations. The key symptoms and signs of cerebellar dysfunction, often grouped under the generic term of ataxia, are discussed. Vertigo, dizziness, and imbalance are associated with lesions of the vestibulo-cerebellar, vestibulo-spinal, or cerebellar ocular motor systems. The cerebellum plays a major role in the online to long-term control of eye movements (control of calibration, reduction of eye instability, maintenance of ocular alignment). Ocular instability, nystagmus, saccadic intrusions, impaired smooth pursuit, impaired vestibulo-ocular reflex (VOR), and ocular misalignment are at the core of oculomotor cerebellar deficits. As a motor speech disorder, ataxic dysarthria is highly suggestive of cerebellar pathology. Regarding motor control of limbs, hypotonia, a- or dysdiadochokinesia, dysmetria, grasping deficits and various tremor phenomenologies are observed in cerebellar disorders to varying degrees. There is clear evidence that the cerebellum participates in force perception and proprioceptive sense during active movements. Gait is staggering with a wide base, and tandem gait is very often impaired in cerebellar disorders. In terms of cognitive and affective operations, impairments are found in executive functions, visual-spatial processing, linguistic function, and affective regulation (Schmahmann's syndrome). Nonmotor linguistic deficits including disruption of articulatory and graphomotor planning, language dynamics, verbal fluency, phonological, and semantic word retrieval, expressive and receptive syntax, and various aspects of reading and writing may be impaired after cerebellar damage. The cerebellum is organized into (a) a primary sensorimotor region in the anterior lobe and adjacent part of lobule VI, (b) a second sensorimotor region in lobule VIII, and (c) cognitive and limbic regions located in the posterior lobe (lobule VI, lobule VIIA which includes crus I and crus II, and lobule VIIB). The limbic cerebellum is mainly represented in the posterior vermis. The cortico-ponto-cerebellar and cerebello-thalamo-cortical loops establish close functional connections between the cerebellum and the supratentorial motor, paralimbic and association cortices, and cerebellar symptoms are associated with a disruption of these loops.
Collapse
Affiliation(s)
- Florian Bodranghien
- FNRS ULB-Erasme, Unité d'Etude du Mouvement, 808 Route de Lennik, 1070, Brussels, Belgium
| | - Amy Bastian
- Kennedy Krieger Institute, 707 N. Broadway, Baltimore, MD, 21205, USA
| | - Carlo Casali
- Department of Medical and Surgical Sciences and Biotechnologies, Rome Sapienza University, Rome, Italy
| | - Mark Hallett
- Human Motor Control Section, NINDS, Bethesda, MD, USA
| | - Elan D Louis
- Department of Neurology, Yale School of Medicine, New Haven, CT, USA
| | - Mario Manto
- FNRS ULB-Erasme, Unité d'Etude du Mouvement, 808 Route de Lennik, 1070, Brussels, Belgium.
| | - Peter Mariën
- Clinical and Experimental Neurolinguistics, CLIN, Vrije Universiteit Brussel, Pleinlaan 2, 1050, Brussels, Belgium
- Department of Neurology and Memory Clinic, ZNA Middelheim General Hospital, Antwerp, Belgium
| | - Dennis A Nowak
- Helios Klinik Kipfenberg, Kindingerstrasse 13, D-85110, Kipfenberg, Germany
- Neurologische Universitätsklinik, Philipps-Universität Marburg, Baldingerstraße, D-35043, Marburg, Germany
| | - Jeremy D Schmahmann
- Ataxia Unit, Cognitive Behavioural Neurology Unit, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA
| | - Mariano Serrao
- Department of Medical and Surgical Sciences and Biotechnologies, Rome Sapienza University, Rome, Italy
- Rehabilitation Centre, Movement Analysis LAB, Policlinico Italia, Rome, Italy
| | - Katharina Marie Steiner
- Department of Neurology, University Clinic Essen, Hufelandstrasse 55, 45147, Essen, Germany
- Department of Neurology, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany
| | | | - Caroline Tilikete
- CRNL INSERM U1028 CNRS UMR5292, Team ImpAct, Bron, F-69676, France
- Lyon I University, Lyon, F-69373, France
- Hospices Civils de Lyon, Neuro-Ophthalmology and Neurology D, Hôpital Neurologique Pierre Wertheimer, Bron, F-69677, France
| | - Dagmar Timmann
- Department of Neurology, University Clinic Essen, Hufelandstrasse 55, 45147, Essen, Germany
- Department of Neurology, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany
| | - Kim van Dun
- Department of Neurology and Memory Clinic, ZNA Middelheim General Hospital, Antwerp, Belgium
| |
Collapse
|
29
|
Fourtassi M, Rode G, Tilikete C, Pisella L. Spontaneous ocular positioning during visual imagery in patients with hemianopia and/or hemineglect. Neuropsychologia 2016; 86:141-52. [PMID: 27129436 DOI: 10.1016/j.neuropsychologia.2016.04.024] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Revised: 04/16/2016] [Accepted: 04/25/2016] [Indexed: 11/28/2022]
Abstract
Spontaneous eye movements during imagery are not random and can be used to study and reveal mental visualization processes (Fourtassi et al., 2013; Johansson et al. 2006). For example, we previously showed that during memory recall of French towns via imagery healthy individuals looks straight ahead when recalling Paris and their subsequent gaze positions are significantly correlated with the real GPS coordinates of the recalled towns. This correlation suggests that memory retrieval is done via depictive representations as it is never found when the towns are recalled using verbal fluency. In the present paper we added to this finding by showing that the mental image is spontaneously centered on the head or body midline. In order to investigate the capacities of visual imagery in patients, and by extension, the role of primary visual cortex and fronto-parietal cortex in spatial visual imagery, we recorded gaze positions during memory recall of French towns in an imagery task, a non-imagery task (verbal fluency), and a visually-guided task in five patients with left or right hemianopia and in four patients with hemineglect (two with left hemianopia and two without). The correlation between gaze position and real GPS coordinates of the recalled towns was significant in all hemianopic patients, but in patients with hemineglect this was only the case for towns located on the right half of the map of France. This suggests hemianopic patients can perform spatially consistent mental imagery despite direct or indirect unilateral lesions of the primary visual cortex. In contrast, the left-sided towns recalled by hemineglect patients, revealed that they have some spatial inconsistency or representational difficulty. Hemianopic patients positioned and maintained their gaze in their contralesional hemispace, suggesting that their mental map was not centered on their head or body midline. This contralesional gaze positioning appeared to be a general compensation strategy and was not observed in patients with neglect (with or without hemianopia). Instead, neglect patients positioned their gaze in their ipsilesional hemispace and only when performing the visual imagery task. These findings are discussed in the context of the role of occipital and fronto-parietal cortices in the neuroanatomical model of visual imagery developed by Kosslyn et al. (2006).
Collapse
Affiliation(s)
- Maryam Fourtassi
- INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, ImpAct, 16 Avenue du Doyen Lépine, 69676 Bron cedex, France; Université Mohamed Premier, Oujda, Morocco
| | - Gilles Rode
- INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, ImpAct, 16 Avenue du Doyen Lépine, 69676 Bron cedex, France; Université Lyon1, Villeurbanne, France; Hospices Civils de Lyon, Hôpital Henry Gabrielle, Mouvement et Handicap, F-69000 Lyon, France
| | - Caroline Tilikete
- INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, ImpAct, 16 Avenue du Doyen Lépine, 69676 Bron cedex, France; Université Lyon1, Villeurbanne, France; Hospices Civils de Lyon, Unité de Neuro-ophtalmologie, Hôpital Neurologique, F-69000 Lyon, France
| | - Laure Pisella
- INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, ImpAct, 16 Avenue du Doyen Lépine, 69676 Bron cedex, France; Université Lyon1, Villeurbanne, France
| |
Collapse
|
30
|
Lévy-Bencheton D, Pélisson D, Prost M, Jacquin-Courtois S, Salemme R, Pisella L, Tilikete C. The Effects of Short-Lasting Anti-Saccade Training in Homonymous Hemianopia with and without Saccadic Adaptation. Front Behav Neurosci 2016; 9:332. [PMID: 26778986 PMCID: PMC4700208 DOI: 10.3389/fnbeh.2015.00332] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2015] [Accepted: 11/19/2015] [Indexed: 11/13/2022] Open
Abstract
Homonymous Visual Field Defects (HVFD) are common following stroke and can be highly debilitating for visual perception and higher level cognitive functions such as exploring visual scene or reading a text. Rehabilitation using oculomotor compensatory methods with automatic training over a short duration (~15 days) have been shown as efficient as longer voluntary training methods (>1 month). Here, we propose to evaluate and compare the effect of an original HVFD rehabilitation method based on a single 15 min voluntary anti-saccades task (AS) toward the blind hemifield, with automatic sensorimotor adaptation to increase AS amplitude. In order to distinguish between adaptation and training effect, 14 left- or right-HVFD patients were exposed, 1 month apart, to three trainings, two isolated AS task (Delayed-shift and No-shift paradigm), and one combined with AS adaptation (Adaptation paradigm). A quality of life questionnaire (NEI-VFQ 25) and functional measurements (reading speed, visual exploration time in pop-out and serial tasks) as well as oculomotor measurements were assessed before and after each training. We could not demonstrate significant adaptation at the group level, but we identified a group of nine adapted patients. While AS training itself proved to demonstrate significant functional improvements in the overall patient group, we could also demonstrate in the sub-group of adapted patients and specifically following the adaptation training, an increase of saccade amplitude during the reading task (left-HVFD patients) and the Serial exploration task, and improvement of the visual quality of life. We conclude that short-lasting AS training combined with adaptation could be implemented in rehabilitation methods of cognitive dysfunctions following HVFD. Indeed, both voluntary and automatic processes have shown interesting effects on the control of visually guided saccades in different cognitive tasks.
Collapse
Affiliation(s)
- Delphine Lévy-Bencheton
- Neuroscience Research Center - Institut National de la Santé et de la Recherche Médicale U 1028 - Centre National de la Recherche Scientifique UMR 5292 Bron, France
| | - Denis Pélisson
- Neuroscience Research Center - Institut National de la Santé et de la Recherche Médicale U 1028 - Centre National de la Recherche Scientifique UMR 5292 Bron, France
| | - Myriam Prost
- Neuroscience Research Center - Institut National de la Santé et de la Recherche Médicale U 1028 - Centre National de la Recherche Scientifique UMR 5292Bron, France; Unité de Neuro-ophtalmologie, Hospices Civils de Lyon, Hôpital Neurologique Pierre WertheimerBron, France
| | - Sophie Jacquin-Courtois
- Neuroscience Research Center - Institut National de la Santé et de la Recherche Médicale U 1028 - Centre National de la Recherche Scientifique UMR 5292Bron, France; University Lyon 1Lyon, France; Hospices Civils de Lyon, Hôpital Henry GabrielleSaint Genis-Laval, France
| | - Roméo Salemme
- Neuroscience Research Center - Institut National de la Santé et de la Recherche Médicale U 1028 - Centre National de la Recherche Scientifique UMR 5292 Bron, France
| | - Laure Pisella
- Neuroscience Research Center - Institut National de la Santé et de la Recherche Médicale U 1028 - Centre National de la Recherche Scientifique UMR 5292 Bron, France
| | - Caroline Tilikete
- Neuroscience Research Center - Institut National de la Santé et de la Recherche Médicale U 1028 - Centre National de la Recherche Scientifique UMR 5292Bron, France; Unité de Neuro-ophtalmologie, Hospices Civils de Lyon, Hôpital Neurologique Pierre WertheimerBron, France; University Lyon 1Lyon, France
| |
Collapse
|
31
|
Malclès A, Ronsin S, Agard E, Abouaf L, Tilikete C, Vighetto A, Biotti D. Isolated oculomotor nerve palsy revealing infectious mononucleosis. Acta Ophthalmol 2015; 93:e518-9. [PMID: 25752335 DOI: 10.1111/aos.12636] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Ariane Malclès
- Neuro-Ophthalmology Unit; Lyon Civil Hospitals; Neurological Hospital; Lyon 1 University; Bron Cedex France
| | - Solène Ronsin
- Neuro-Ophthalmology Unit; Lyon Civil Hospitals; Neurological Hospital; Lyon 1 University; Bron Cedex France
| | - Emilie Agard
- Neuro-Ophthalmology Unit; Lyon Civil Hospitals; Neurological Hospital; Lyon 1 University; Bron Cedex France
| | - Lucie Abouaf
- Neuro-Ophthalmology Unit; Lyon Civil Hospitals; Neurological Hospital; Lyon 1 University; Bron Cedex France
| | - Caroline Tilikete
- Neuro-Ophthalmology Unit; Lyon Civil Hospitals; Neurological Hospital; Lyon 1 University; Bron Cedex France
| | - Alain Vighetto
- Neuro-Ophthalmology Unit; Lyon Civil Hospitals; Neurological Hospital; Lyon 1 University; Bron Cedex France
| | - Damien Biotti
- Neuro-Ophthalmology Unit; Lyon Civil Hospitals; Neurological Hospital; Lyon 1 University; Bron Cedex France
| |
Collapse
|
32
|
Khan AZ, Prost-Lefebvre M, Salemme R, Blohm G, Rossetti Y, Tilikete C, Pisella L. The Attentional Fields of Visual Search in Simultanagnosia and Healthy Individuals: How Object and Space Attention Interact. Cereb Cortex 2015; 26:1242-54. [PMID: 25840422 DOI: 10.1093/cercor/bhv059] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Simultanagnosia is a deficit in which patients are unable to perceive multiple objects simultaneously. To date, it remains disputed whether this deficit results from disrupted object or space perception. We asked both healthy participants as well as a patient with simultanagnosia to perform different visual search tasks of variable difficulty. We also modulated the number of objects (target and distracters) presented. For healthy participants, we found that each visual search task was performed with a specific "attentional field" depending on the difficulty of visual object processing but not on the number of objects falling within this "working space." This was demonstrated by measuring the cost in reaction times using different gaze-contingent visible window sizes. We found that bilateral damage to the superior parietal lobule impairs the spatial integration of separable features (within-object processing), shrinking the attentional field in which a target can be detected, but causing no deficit in processing multiple objects per se.
Collapse
Affiliation(s)
- A Z Khan
- ImpAct - Lyon Neuroscience Research Center, Inserm U1028, CNRS UMR 5292, Bron, France Université de Lyon, Biologie Humaine, Bron, France Hospices Civils de Lyon, Bron, France School of Optometry, University of Montreal, Montreal, QC, Canada
| | - M Prost-Lefebvre
- ImpAct - Lyon Neuroscience Research Center, Inserm U1028, CNRS UMR 5292, Bron, France Université de Lyon, Biologie Humaine, Bron, France Hospices Civils de Lyon, Bron, France
| | - R Salemme
- ImpAct - Lyon Neuroscience Research Center, Inserm U1028, CNRS UMR 5292, Bron, France Université de Lyon, Biologie Humaine, Bron, France Hospices Civils de Lyon, Bron, France
| | - G Blohm
- Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada
| | - Y Rossetti
- ImpAct - Lyon Neuroscience Research Center, Inserm U1028, CNRS UMR 5292, Bron, France Université de Lyon, Biologie Humaine, Bron, France Hospices Civils de Lyon, Bron, France
| | - C Tilikete
- ImpAct - Lyon Neuroscience Research Center, Inserm U1028, CNRS UMR 5292, Bron, France Université de Lyon, Biologie Humaine, Bron, France Hospices Civils de Lyon, Bron, France
| | - L Pisella
- ImpAct - Lyon Neuroscience Research Center, Inserm U1028, CNRS UMR 5292, Bron, France Université de Lyon, Biologie Humaine, Bron, France Hospices Civils de Lyon, Bron, France
| |
Collapse
|
33
|
Biotti D, Esteban-Mader M, Diot E, Acquaviva C, Guffon N, Tilikete C, Benoist JF, Labauge P, Vighetto A. Clinical reasoning: A young woman with rapid mental deterioration and leukoencephalopathy: a treatable cause. Neurology 2015; 83:e182-6. [PMID: 25404648 DOI: 10.1212/wnl.0000000000001006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Damien Biotti
- From the Departments of Neurology (D.B., M.E.-M., C.T., A.V.) and Neuro-ophthalmology (D.B., C.T., A.V.), Hôpital Neurologique Pierre Wertheimer, Lyon; Université de Lyon 1 (D.B., C.T., A.V.), Université Claude Bernard; Department of Neurology (E.D.), Centre Hospitalier de Vienne; Service des Maladies Héréditaires du Métabolisme et Centre de Référence des Maladies Héréditaires du Métabolisme (C.A., N.G.), HFME, Lyon; Service de Biochimie-Hormonologie (J.-F.B.), APHP-Hôpital Robert Debré, Paris; and Service de Neurologie (P.L.), CHRU Gui-de-Chauliac, Montpellier, France.
| | - Maud Esteban-Mader
- From the Departments of Neurology (D.B., M.E.-M., C.T., A.V.) and Neuro-ophthalmology (D.B., C.T., A.V.), Hôpital Neurologique Pierre Wertheimer, Lyon; Université de Lyon 1 (D.B., C.T., A.V.), Université Claude Bernard; Department of Neurology (E.D.), Centre Hospitalier de Vienne; Service des Maladies Héréditaires du Métabolisme et Centre de Référence des Maladies Héréditaires du Métabolisme (C.A., N.G.), HFME, Lyon; Service de Biochimie-Hormonologie (J.-F.B.), APHP-Hôpital Robert Debré, Paris; and Service de Neurologie (P.L.), CHRU Gui-de-Chauliac, Montpellier, France
| | - Eric Diot
- From the Departments of Neurology (D.B., M.E.-M., C.T., A.V.) and Neuro-ophthalmology (D.B., C.T., A.V.), Hôpital Neurologique Pierre Wertheimer, Lyon; Université de Lyon 1 (D.B., C.T., A.V.), Université Claude Bernard; Department of Neurology (E.D.), Centre Hospitalier de Vienne; Service des Maladies Héréditaires du Métabolisme et Centre de Référence des Maladies Héréditaires du Métabolisme (C.A., N.G.), HFME, Lyon; Service de Biochimie-Hormonologie (J.-F.B.), APHP-Hôpital Robert Debré, Paris; and Service de Neurologie (P.L.), CHRU Gui-de-Chauliac, Montpellier, France
| | - Cécile Acquaviva
- From the Departments of Neurology (D.B., M.E.-M., C.T., A.V.) and Neuro-ophthalmology (D.B., C.T., A.V.), Hôpital Neurologique Pierre Wertheimer, Lyon; Université de Lyon 1 (D.B., C.T., A.V.), Université Claude Bernard; Department of Neurology (E.D.), Centre Hospitalier de Vienne; Service des Maladies Héréditaires du Métabolisme et Centre de Référence des Maladies Héréditaires du Métabolisme (C.A., N.G.), HFME, Lyon; Service de Biochimie-Hormonologie (J.-F.B.), APHP-Hôpital Robert Debré, Paris; and Service de Neurologie (P.L.), CHRU Gui-de-Chauliac, Montpellier, France
| | - Nathalie Guffon
- From the Departments of Neurology (D.B., M.E.-M., C.T., A.V.) and Neuro-ophthalmology (D.B., C.T., A.V.), Hôpital Neurologique Pierre Wertheimer, Lyon; Université de Lyon 1 (D.B., C.T., A.V.), Université Claude Bernard; Department of Neurology (E.D.), Centre Hospitalier de Vienne; Service des Maladies Héréditaires du Métabolisme et Centre de Référence des Maladies Héréditaires du Métabolisme (C.A., N.G.), HFME, Lyon; Service de Biochimie-Hormonologie (J.-F.B.), APHP-Hôpital Robert Debré, Paris; and Service de Neurologie (P.L.), CHRU Gui-de-Chauliac, Montpellier, France
| | - Caroline Tilikete
- From the Departments of Neurology (D.B., M.E.-M., C.T., A.V.) and Neuro-ophthalmology (D.B., C.T., A.V.), Hôpital Neurologique Pierre Wertheimer, Lyon; Université de Lyon 1 (D.B., C.T., A.V.), Université Claude Bernard; Department of Neurology (E.D.), Centre Hospitalier de Vienne; Service des Maladies Héréditaires du Métabolisme et Centre de Référence des Maladies Héréditaires du Métabolisme (C.A., N.G.), HFME, Lyon; Service de Biochimie-Hormonologie (J.-F.B.), APHP-Hôpital Robert Debré, Paris; and Service de Neurologie (P.L.), CHRU Gui-de-Chauliac, Montpellier, France
| | - Jean-François Benoist
- From the Departments of Neurology (D.B., M.E.-M., C.T., A.V.) and Neuro-ophthalmology (D.B., C.T., A.V.), Hôpital Neurologique Pierre Wertheimer, Lyon; Université de Lyon 1 (D.B., C.T., A.V.), Université Claude Bernard; Department of Neurology (E.D.), Centre Hospitalier de Vienne; Service des Maladies Héréditaires du Métabolisme et Centre de Référence des Maladies Héréditaires du Métabolisme (C.A., N.G.), HFME, Lyon; Service de Biochimie-Hormonologie (J.-F.B.), APHP-Hôpital Robert Debré, Paris; and Service de Neurologie (P.L.), CHRU Gui-de-Chauliac, Montpellier, France
| | - Pierre Labauge
- From the Departments of Neurology (D.B., M.E.-M., C.T., A.V.) and Neuro-ophthalmology (D.B., C.T., A.V.), Hôpital Neurologique Pierre Wertheimer, Lyon; Université de Lyon 1 (D.B., C.T., A.V.), Université Claude Bernard; Department of Neurology (E.D.), Centre Hospitalier de Vienne; Service des Maladies Héréditaires du Métabolisme et Centre de Référence des Maladies Héréditaires du Métabolisme (C.A., N.G.), HFME, Lyon; Service de Biochimie-Hormonologie (J.-F.B.), APHP-Hôpital Robert Debré, Paris; and Service de Neurologie (P.L.), CHRU Gui-de-Chauliac, Montpellier, France
| | - Alain Vighetto
- From the Departments of Neurology (D.B., M.E.-M., C.T., A.V.) and Neuro-ophthalmology (D.B., C.T., A.V.), Hôpital Neurologique Pierre Wertheimer, Lyon; Université de Lyon 1 (D.B., C.T., A.V.), Université Claude Bernard; Department of Neurology (E.D.), Centre Hospitalier de Vienne; Service des Maladies Héréditaires du Métabolisme et Centre de Référence des Maladies Héréditaires du Métabolisme (C.A., N.G.), HFME, Lyon; Service de Biochimie-Hormonologie (J.-F.B.), APHP-Hôpital Robert Debré, Paris; and Service de Neurologie (P.L.), CHRU Gui-de-Chauliac, Montpellier, France
| |
Collapse
|
34
|
Mathis T, Ducray F, Tilikete C, Vighetto A, Biotti D. Pontine infarction responsible for wall-eyed bilateral internuclear ophthalmoplegia syndrome. Neurol Clin Pract 2014; 4:524-525. [PMID: 29443142 DOI: 10.1212/cpj.0000000000000063] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Thibaud Mathis
- Department of Ophthalmology (TM), Croix Rousse Hospital; Departments of Neuro-oncology (FD), Neurology, and Neuro-ophthalmology (CT, AV, DB), Hôpital Neurologique Pierre Wertheimer; and Université de Lyon 1-Université Claude Bernard (CT, AV, DB), Lyon, France
| | - François Ducray
- Department of Ophthalmology (TM), Croix Rousse Hospital; Departments of Neuro-oncology (FD), Neurology, and Neuro-ophthalmology (CT, AV, DB), Hôpital Neurologique Pierre Wertheimer; and Université de Lyon 1-Université Claude Bernard (CT, AV, DB), Lyon, France
| | - Caroline Tilikete
- Department of Ophthalmology (TM), Croix Rousse Hospital; Departments of Neuro-oncology (FD), Neurology, and Neuro-ophthalmology (CT, AV, DB), Hôpital Neurologique Pierre Wertheimer; and Université de Lyon 1-Université Claude Bernard (CT, AV, DB), Lyon, France
| | - Alain Vighetto
- Department of Ophthalmology (TM), Croix Rousse Hospital; Departments of Neuro-oncology (FD), Neurology, and Neuro-ophthalmology (CT, AV, DB), Hôpital Neurologique Pierre Wertheimer; and Université de Lyon 1-Université Claude Bernard (CT, AV, DB), Lyon, France
| | - Damien Biotti
- Department of Ophthalmology (TM), Croix Rousse Hospital; Departments of Neuro-oncology (FD), Neurology, and Neuro-ophthalmology (CT, AV, DB), Hôpital Neurologique Pierre Wertheimer; and Université de Lyon 1-Université Claude Bernard (CT, AV, DB), Lyon, France
| |
Collapse
|
35
|
Agard E, Biotti D, Malclès A, Vighetto A, Tilikete C, Desestret V. WITHDRAWN: A third nerve palsy with an Argyll Robertson pupil. IDCases 2014. [DOI: 10.1016/j.idcr.2014.10.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
36
|
Lévy-Bencheton D, Pélisson D, Panouillères M, Urquizar C, Tilikete C, Pisella L. Adaptation of scanning saccades co-occurs in different coordinate systems. J Neurophysiol 2014; 111:2505-15. [PMID: 24647436 DOI: 10.1152/jn.00733.2013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Plastic changes of saccades (i.e., following saccadic adaptation) do not transfer between oppositely directed saccades, except when multiple directions are trained simultaneously, suggesting a saccadic planning in retinotopic coordinates. Interestingly, a recent study in human healthy subjects revealed that after an adaptive increase of rightward-scanning saccades, both leftward and rightward double-step, memory-guided saccades, triggered toward the adapted endpoint, were modified, revealing that target location was coded in spatial coordinates (Zimmermann et al. 2011). However, as the computer screen provided a visual frame, one alternative hypothesis could be a coding in allocentric coordinates. Here, we questioned whether adaptive modifications of saccadic planning occur in multiple coordinate systems. We reproduced the paradigm of Zimmermann et al. (2011) using target light-emitting diodes in the dark, with and without a visual frame, and tested different saccades before and after adaptation. With double-step, memory-guided saccades, we reproduced the transfer of adaptation to leftward saccades with the visual frame but not without, suggesting that the coordinate system used for saccade planning, when the frame is visible, is allocentric rather than spatiotopic. With single-step, memory-guided saccades, adaptation transferred to leftward saccades, both with and without the visual frame, revealing a target localization in a coordinate system that is neither retinotopic nor allocentric. Finally, with single-step, visually guided saccades, the classical, unidirectional pattern of amplitude change was reproduced, revealing retinotopic coordinate coding. These experiments indicate that the same procedure of adaptation modifies saccadic planning in multiple coordinate systems in parallel-each of them revealed by the use of different saccade tasks in postadaptation.
Collapse
Affiliation(s)
- Delphine Lévy-Bencheton
- Lyon Neuroscience Research Center, INSERM U1028, CNRS UMR5292, Team ImpAct, Bron, France; Lyon I University, Lyon, France; and
| | - Denis Pélisson
- Lyon Neuroscience Research Center, INSERM U1028, CNRS UMR5292, Team ImpAct, Bron, France; Lyon I University, Lyon, France; and
| | - Muriel Panouillères
- Lyon Neuroscience Research Center, INSERM U1028, CNRS UMR5292, Team ImpAct, Bron, France; Lyon I University, Lyon, France; and
| | - Christian Urquizar
- Lyon Neuroscience Research Center, INSERM U1028, CNRS UMR5292, Team ImpAct, Bron, France
| | - Caroline Tilikete
- Lyon Neuroscience Research Center, INSERM U1028, CNRS UMR5292, Team ImpAct, Bron, France; Lyon I University, Lyon, France; and Hospices Civils de Lyon, Neuro-Ophthalmology Unit, Hôpital Neurologique Pierre Wertheimer, Bron, France
| | - Laure Pisella
- Lyon Neuroscience Research Center, INSERM U1028, CNRS UMR5292, Team ImpAct, Bron, France; Lyon I University, Lyon, France; and
| |
Collapse
|
37
|
Tilikete C. Devant un opsoclonus/flutter. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
38
|
Esteban-Mader M, Diot E, Acquaviva C, Tilikete C, Vighetto A, Biotti D. Un cas de leucoencéphalopathie métabolique de l’adulte, subaiguë, sévère... mais traitable ! L’homocystéine est la clé ! Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Panouillères M, Frismand S, Sillan O, Urquizar C, Vighetto A, Pélisson D, Tilikete C. Saccades and eye-head coordination in ataxia with oculomotor apraxia type 2. Cerebellum 2014; 12:557-67. [PMID: 23475383 DOI: 10.1007/s12311-013-0463-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Ataxia with oculomotor apraxia type 2 (AOA2) is one of the most frequent autosomal recessive cerebellar ataxias. Oculomotor apraxia refers to horizontal gaze failure due to deficits in voluntary/reactive eye movements. These deficits can manifest as increased latency and/or hypometria of saccades with a staircase pattern and are frequently associated with compensatory head thrust movements. Oculomotor disturbances associated with AOA2 have been poorly studied mainly because the diagnosis of oculomotor apraxia was based on the presence of compensatory head thrusts. The aim of this study was to characterise the nature of horizontal gaze failure in patients with AOA2 and to demonstrate oculomotor apraxia even in the absence of head thrusts. Five patients with AOA2, without head thrusts, were tested in saccadic tasks with the head restrained or free to move and their performance was compared to a group of six healthy participants. The most salient deficit of the patients was saccadic hypometria with a typical staircase pattern. Saccade latency in the patients was longer than controls only for memory-guided saccades. In the head-free condition, head movements were delayed relative to the eye and their amplitude and velocity were strongly reduced compared to controls. Our study emphasises that in AOA2, hypometric saccades with a staircase pattern are a more reliable sign of oculomotor apraxia than head thrust movements. In addition, the variety of eye and head movements' deficits suggests that, although the main neural degeneration in AOA2 affects the cerebellum, this disease affects other structures.
Collapse
Affiliation(s)
- Muriel Panouillères
- INSERM U1028; CNRS UMR5292; Lyon Neuroscience Research Center, ImpAct Team, Bron, 69676, France.
| | | | | | | | | | | | | |
Collapse
|
40
|
Savary P, Biotti D, Abouaf L, Bernard M, Chaise F, Guerrier O, Tilikete C, Vighetto A. Poppers toxic maculopathy misdiagnosed as atypical optic neuritis. Eur J Neurol 2014; 20:e90-1. [PMID: 23750837 DOI: 10.1111/ene.12148] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2013] [Accepted: 02/14/2013] [Indexed: 11/29/2022]
|
41
|
Benoilid A, Tilikete C, Collongues N, Arndt C, Vighetto A, Vignal C, de Seze J. Relapsing optic neuritis: a multicentre study of 62 patients. Mult Scler 2013; 20:848-53. [DOI: 10.1177/1352458513510223] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Accepted: 09/11/2013] [Indexed: 11/17/2022]
Abstract
Background: Optic neuritis (ON) may be the first symptom of a central nervous system demyelinating, systemic or infectious disease but few patients experience recurrent episodes and have a negative workup. Objective: This disorder, named relapsing optic neuritis (RON), is poorly described in the literature and still presents a particular challenge in diagnosis and management. Methods: We describe the clinical, laboratory, magnetic resonance imaging (MRI) and disability course of RON in a French cohort of 62 patients, based on a multicentre, retrospective, observational study. Results: In our cohort, we identified two distinct groups of RON patients. The first is characterised by relapsing inflammatory optic neuritis (RION, 68%), which is non-progressive, whereas the second presented as a chronic relapsing inflammatory optic neuritis (CRION, 32%), which is progressive. We have noted more cases with steroid dependence in the CRION group than the RION group (42% vs 10%). The long-term visual prognosis was more severe in CRION patients and neuromyelitis optica-immunoglobulin G (NMO-IgG)-positive patients. Conclusion: RON is likely a separate entity corresponding to an autoimmune disease that differs from multiple sclerosis (MS), NMO and vasculitis. We provide a new classification system based on a better understanding of RON which could allow an improved management by early treatment of poor prognosis forms.
Collapse
Affiliation(s)
- Aurélien Benoilid
- University Hospital, France
- Clinical Investigation Centre, INSERM 10002, France
| | | | - Nicolas Collongues
- University Hospital, France
- Clinical Investigation Centre, INSERM 10002, France
| | | | | | | | - Jérôme de Seze
- University Hospital, France
- Clinical Investigation Centre, INSERM 10002, France
| |
Collapse
|
42
|
Ong E, Biotti D, Abouaf L, Louis-Tisserand G, Tilikete C, Vighetto A. Teaching NeuroImages: Chiasmal enlargement and enhancement in Leber hereditary optic neuropathy. Neurology 2013; 81:e126-7. [DOI: 10.1212/wnl.0b013e3182a95698] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
43
|
|
44
|
Panouillères M, Alahyane N, Urquizar C, Salemme R, Nighoghossian N, Gaymard B, Tilikete C, Pélisson D. Effects of structural and functional cerebellar lesions on sensorimotor adaptation of saccades. Exp Brain Res 2013; 231:1-11. [PMID: 23963603 DOI: 10.1007/s00221-013-3662-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Accepted: 07/28/2013] [Indexed: 11/24/2022]
Abstract
The cerebellum is critically involved in the adaptation mechanisms that maintain the accuracy of goal-directed acts such as saccadic eye movements. Two categories of saccades, each relying on different adaptation mechanisms, are defined: reactive (externally triggered) saccades and voluntary (internally triggered) saccades. The contribution of the medio-posterior part of the cerebellum to reactive saccades adaptation has been clearly demonstrated, but the evidence that other parts of the cerebellum are also involved is limited. Moreover, the cerebellar substrates of voluntary saccades adaptation have only been marginally investigated. Here, we addressed these two questions by investigating the adaptive capabilities of patients with cerebellar or pre-cerebellar stroke. We recruited three groups of patients presenting focal lesions located, respectively, in the supero-anterior cerebellum, the infero-posterior cerebellum and the lateral medulla (leading to a Wallenberg syndrome including motor dysfunctions similar to those resulting from lesion of the medio-posterior cerebellum). Adaptations of reactive saccades and of voluntary saccades were tested during separate sessions in all patients and in a group of healthy participants. The functional lesion of the medio-posterior cerebellum in Wallenberg syndrome strongly impaired the adaptation of both reactive and voluntary saccades. In contrast, patients with lesion in the supero-anterior part of the cerebellum presented a specific adaptation deficit of voluntary saccades. Finally, patients with an infero-posterior cerebellar lesion showed mild adaptation deficits. We conclude that the medio-posterior cerebellum is critical for the adaptation of both saccade categories, whereas the supero-anterior cerebellum is specifically involved in the adaptation of voluntary saccades.
Collapse
Affiliation(s)
- M Panouillères
- INSERM U1028, CNRS UMR5292, ImpAct Team, Lyon Neuroscience Research Center, 69000, Lyon, France,
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Clément G, Tilikete C, Courjon JH. Influence of stimulus interval on the habituation of vestibulo-ocular reflex and sensation of rotation in humans. Neurosci Lett 2013; 549:40-4. [DOI: 10.1016/j.neulet.2013.06.038] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2013] [Revised: 05/11/2013] [Accepted: 06/20/2013] [Indexed: 10/26/2022]
|
46
|
Levy-Bencheton D, Pelisson D, Panouilleres M, Urquizar C, Tilikete C, Pisella L. Adaptation of saccadic eye movements involves different coordinate systems. J Vis 2013. [DOI: 10.1167/13.9.1217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
47
|
Frismand S, Salem H, Panouilleres M, Pélisson D, Jacobs S, Vighetto A, Cotton F, Tilikete C. MRI findings in AOA2: Cerebellar atrophy and abnormal iron detection in dentate nucleus. Neuroimage Clin 2013; 2:542-8. [PMID: 24179805 PMCID: PMC3777765 DOI: 10.1016/j.nicl.2013.03.018] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/24/2012] [Revised: 02/22/2013] [Accepted: 03/27/2013] [Indexed: 12/20/2022]
Abstract
Ataxia with Oculomotor Apraxia type 2 (AOA2) is one of the most frequent types of autosomal degenerative cerebellar ataxia. The first objective of this work was to identify specific cerebellar atrophy using MRI in patients with AOA2. Since increased iron deposits have been reported in degenerative diseases, our second objective was to report iron deposits signals in the dentate nuclei in AOA2. Five patients with AOA2 and 5 age-matched controls were subjects in a 3T MRI experiment that included a 3D turbo field echo T1-weighted sequence. The normalized volumes of twenty-eight cerebellar lobules and the percentage of atrophy (relative to controls) of the 4 main cerebellar regions (flocculo-nodular, vermis, anterior and posterior) were measured. The dentate nucleus signals using 3D fast field echo sequence for susceptibility-weighted images (SWI) were reported, as a measure of iron content. We found that all patients had a significant atrophy of all cerebellar lobules as compared to controls. The percentage of atrophy was the highest for the vermis, consistent with patients' oculomotor presentation, and for the anterior lobe, consistent with kinetic limb ataxia. We also describe an absence of hypointensity of the iron signal on SWI in the dentate nucleus of all patients compared to control subjects. This study suggests that patients with Ataxia with Oculomotor Apraxia type 2 present MRI patterns consistent with their clinical presentation. The absence of SWI hypointensity in dentate nucleus is a new radiological sign which was identified in all patients. The specificity of this absence of signal must be further determined in AOA2.
Collapse
Affiliation(s)
- Solène Frismand
- Hospices Civils de Lyon, Neuro-ophtalmology Unit and Neurology D, Neurological and Neurosurgical Hospital P. Wertheimer, Lyon F-69000, France
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Lebedel N, Tilikete C, Anheim M, Jardel C, Vial C. Hypersignal T2 des olives bulbaires à l’imagerie par résonance magnétique dans un forme familiale d’ataxie cérébelleuse par mutation POLG. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Jasse L, Vukusic S, Durand-Dubief F, Vartin C, Piras C, Bernard M, Pélisson D, Confavreux C, Vighetto A, Tilikete C. Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler 2013; 19:1618-26. [DOI: 10.1177/1352458513479840] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective: The objective of this article is to evaluate in multiple sclerosis (MS) patients the prevalence of persistent complaints of visual disturbances and the mechanisms and resulting functional disability of persistent visual complaints (PVCs). Methods: Firstly, the prevalence of PVCs was calculated in 303 MS patients. MS-related data of patients with or without PVCs were compared. Secondly, 70 patients with PVCs performed an extensive neuro-ophthalmologic assessment and a vision-related quality of life questionnaire, the National Eye Institute Visual Functionary Questionnaire (NEI-VFQ-25). Results: PVCs were reported in 105 MS patients (34.6%). Patients with PVCs had more frequently primary progressive MS (30.5% vs 13.6%) and more neuro-ophthalmologic relapses (1.97 vs 1.36) than patients without PVCs. In the mechanisms/disability study, an afferent visual and an ocular-motor pathways dysfunction were respectively diagnosed in 41 and 59 patients, mostly related to bilateral optic neuropathy and bilateral internuclear ophthalmoplegia. The NEI-VFQ 25 score was poor and significantly correlated with the number of impaired neuro-ophthalmologic tests. Conclusion: Our study emphasizes the high prevalence of PVC in MS patients. Regarding the nature of neuro-ophthalmologic deficit, our results suggest that persistent optic neuropathy, as part of the progressive evolution of the disease, is not rare. We also demonstrate that isolated ocular motor dysfunctions induce visual disability in daily life.
Collapse
Affiliation(s)
- Laurence Jasse
- INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, ImpAct Team, France
- University Lyon, France
| | - Sandra Vukusic
- University Lyon, France
- INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, France
| | - Françoise Durand-Dubief
- Neurology A and EDMUS Coordinating Center for Multiple Sclerosis, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, University Lyon1, France
| | - Cristina Vartin
- Neuro-ophthalmology and Neurology D, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France
| | - Carolina Piras
- Neuro-ophthalmology and Neurology D, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France
| | - Martine Bernard
- Neuro-ophthalmology and Neurology D, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France
| | - Denis Pélisson
- INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, ImpAct Team, France
- University Lyon, France
| | - Christian Confavreux
- University Lyon, France
- INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, Neuro-oncology and Neuro-inflammation Team, France
| | - Alain Vighetto
- INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, ImpAct Team, France
- University Lyon, France
- Neuro-ophthalmology and Neurology D, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France
| | - Caroline Tilikete
- INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, ImpAct Team, France
- University Lyon, France
- Neuro-ophthalmology and Neurology D, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France
| |
Collapse
|
50
|
Lvy-Bencheton D, Plisson D, Prost M, Jacquin-courtois S, Gabrielle H, Salemme R, Pisella L, Tilikete C. Saccadic adaptation for rehabilitation in hemianopic patients. J Vis 2012. [DOI: 10.1167/12.14.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|